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ABSTRACT 
Age-related macular degeneration (AMD) is the most common cause of irreversible 
blindness in older Americans.
 
There has been a long standing interest in the role of diet in the 
development of AMD. As early as the first National Health and Nutrition Examination Survey in 
the 1970s, higher intakes of fruits and vegetables were inversely correlated with the prevalence 
of AMD. Carotenoids and omega3 fatty acids are the most studied dietary factors due to strong 
biological plausibility. However, evidence from epidemiologic studies and clinical trials on the 
relations has been inconsistent.  
Chapter I prospectively examined the intakes of lutein/zeaxanthin and other common 
carotenoids in relation to the risk of AMD over more than two decades of follow-up among two 
large US cohorts, the Nurses’ Health Study and Health Professionals Follow-Up Study. We 
assessed nutrient intakes by repeated food frequency questionnaires. We also computed 
bioavailable plasma carotenoid scores directly from food intake using validated regression 
models. Cox proportional hazards models were used to compute the associations. Higher intakes 
of bioavailable carotenoids (except lycopene) were inversely associated with advanced AMD but 
not intermediate AMD. Analyses based on bioavailable intakes resulted in stronger associations 
than conventional nutrient intakes.  
Chapter II prospectively evaluated the marine long-chain omega3 fatty acids. We found 
that long-chain omega3 fatty acids were inversely associated with visually significant 
iii 
 
intermediate AMD. There was no association with advanced AMD; however, the totality of 
current evidence for advanced AMD is also discordant. 
Chapter III further investigated the plant-derived omega3 fatty acids, α-linolenic acid 
(ALA). We found that higher intake of ALA was associated with intermediate AMD before 2002 
but not after. This coincides with the same time period when trans ALA was found in our 
participants’ blood and in mayonnaise, a primary food source of ALA. Whether trans ALA 
mediates this positive association warrants further studies. 
Although randomized trials are usually believed as the “gold standard”, dietary factors are 
hard to be adequately studied by randomized trials due to the complexities of diet and disease 
relations. Thus, findings in this thesis from large long-term prospective cohort studies provide 
the next best form of evidence. 
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ABSTRACT 
Importance: Despite strong biologic plausibility, evidence from epidemiologic studies and 
clinical trials on the relations between intakes of lutein and zeaxanthin and age-related macular 
degeneration (AMD) has been inconsistent. The roles of other carotenoids are less thoroughly 
investigated. 
Objective: To investigate the associations between intakes of carotenoids and AMD. 
Design: Prospective cohort study.  
Setting: Nurses’ Health Study and Health Professionals Follow-Up Study. 
Participants: 63,443 women and 38,603 men were followed from 1984 and 1986, respectively, 
until 2010. All participants were 50 years and older, and free of diagnosed AMD, diabetes, 
cardiovascular disease and cancer at baseline. 
Exposure: We assessed food intake by repeated food frequency questionnaires at baseline and 
follow-up. We computed predicted plasma carotenoid scores directly from food intake using 
validated regression models to account for bioavailability and reporting validity of different 
foods. 
Main Outcome and Measure: We confirmed 1,361 incident intermediate and 1,118 advanced 
AMD cases (primarily neovascular AMD) with a visual acuity of 20/30 or worse by medical 
record review.  
Results: In analyses based on a predicted plasma lutein/zeaxanthin score, we found a risk 
reduction for advanced AMD of about 40% in both women and men (pooled hazard ratio 
comparing extreme quintiles = 0.59, 95% CI = 0.48 - 0.73; p for trend, <0.001). Other predicted 
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plasma carotenoid scores, including β-cryptoxanthin, α-carotene and β-carotene, were associated 
with a 25% to 35% lower risk of advanced AMD. The hazard ratio comparing extreme quintiles 
for the predicted plasma total carotenoid index was 0.65 (95% CI = 0.53 - 0.80; p for trend, 
<0.001). We did not identify any associations of carotenoids, either as predicted plasma score or 
calculated intake, with intermediate AMD. 
Conclusion: Higher intake of bioavailable lutein/zeaxanthin is associated with a long-term 
reduced risk of advanced AMD. Given that some other carotenoids are also associated with a 
lower risk, a public health strategy aimed at increasing dietary consumption of a wide variety of 
fruits and vegetables rich in carotenoids may reduce the incidence of advanced AMD. 
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I. Introduction  
Age-related macular degeneration (AMD) is the leading cause of blindness in the developed 
world,
1,2
 affecting 6.5% of persons aged 40 years and older in the US, with 0.8% afflicted by 
advanced AMD.
3
 The prevalence of AMD prevalence is projected to increase by 50% in the next 
couple of decades
4-6
 as a consequence of exponential population aging, the lack of a cure or any 
effective means of primary prevention other than smoking cessation.
7
 
Carotenoids are fat-soluble plant pigments found in red, yellow, orange and dark-green fruits and 
vegetables. Of more than 600 carotenoids, 6 are commonly found in the human diet and serum: 
lutein, zeaxanthin, α-carotene, β-carotene, lycopene and β-cryptoxanthin.8 Lutein and zeaxanthin 
are selectively concentrated in the macula,
9,10
 where they are hypothesized to protect against 
AMD by absorbing blue light, quenching free radicals and stabilizing cell membranes.
11
 
However, in spite of compelling biologic plausibility, epidemiologic studies have not yielded 
consistent findings
12-15
 and long-term, well-powered prospective cohort studies are lacking. The 
recently concluded Age-Related Eye Disease Study 2 (AREDS 2) trial was unable to confidently 
demonstrate protective effects of lutein/zeaxanthin
16,17
 and whether lutein/zeaxanthin may 
protect against early AMD also remains unknown. Some other carotenoids, such as α-carotene, 
β-carotene and lycopene, found in the retinal pigment epithelium (RPE) and choroid,18 have been 
inconsistently linked to a lower risk of AMD.
12-15,19,20
  
We previously reported a suggestive inverse association of lutein/zeaxanthin with advanced 
AMD
21
 and some associations for other carotenoids.
22
 With an additional decade of follow-up 
and the occurrence of a large number of additional incident AMD cases, we aimed to provide 
more detailed insights into the roles of carotenoids in the development of AMD. 
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II. Methods 
Study Population 
The Nurses’ Health Study (NHS) is an ongoing prospective cohort initiated in 1976 that includes 
121,700 US female registered nurses aged 30 to 55 years at baseline. The Health Professionals 
Follow-up Study (HPFS) was initiated in 1986 and includes 51,529 US male health professionals 
aged 40 to 75 years at baseline. Both cohorts are predominantly white (NHS: >98%; 
HPFS: >91%), and have high rates of long-term follow-up (>95%). The study protocol was 
approved by the Institutional Review Boards at the Brigham and Women's Hospital and Harvard 
T.H. Chan School of Public Health. 
We restricted the study population to participants ≥50 years, and censored participants at age 90 
to alleviate concerns of low reporting validity (NHS, n=0; HPFS, n=526). At baseline, we 
excluded participants who did not return the initial FFQ, left the entire fruit and vegetable 
sections blank or had more than 70 food items blank, reported implausible dietary intake (<500 
or >3500 Kcal/d for the NHS and <800 or > 4200 Kcal/d for the HPFS) (dietary exclusions, NHS, 
n=46,142; HPFS, n=1,647), had prevalent AMD, cancer (except nonmelanoma skin cancer), 
diabetes or cardiovascular disease (disease exclusions, NHS, n=8,536; HPFS, n=5,709). To 
minimize detection bias, we also excluded participants who never reported an eye exam over 
follow-up (NHS, n=3,362; HPFS, n=4,763) and excluded from analysis the person-time during 
any two-year interval in which a participant did not report an eye exam. In sensitivity analyses 
including intervals lacking an eye exam results did not materially change. Participants 
contributed person-time to the analysis from the return of baseline questionnaire or reaching 50 
years old to the confirmed diagnosis of AMD, death, loss to follow-up or the end of follow-up 
(05/31/2010 for the NHS and 01/31/2010 for the HPFS), whichever occurred first. By 2010, a 
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total of 63,443 women and 38,603 men contributed to the analysis.  
AMD Ascertainment 
Our case definition has been previously validated.
23
 When a participant reported a diagnosis of 
AMD on a biennial questionnaire, we requested informed consent and then contacted the 
participant’s eye doctor to confirm the diagnosis by review of medical records. We excluded 
cases with only small hard drusen (< 63μm diameter). We defined intermediate AMD as having 
at least one of the following signs: intermediate drusen (≥ 63 and <125 µm), pigment 
abnormalities, large drusen (≥ 125 µm) or any non-central geographic atrophy (GA). We defined 
a subgroup of intermediate AMD as having at least one large druse or any non-central GA, the 
most likely to progress to advanced AMD.
24
 We defined neovascular AMD as having any of the 
following: RPE detachment, subretinal neovascular membrane, disciform scar, or history of 
treatment with laser, photodynamic, or anti-VEGF therapy for AMD. Central GA was defined as 
having a central geographic atrophy lesion involving the center of the macula. Advanced AMD 
included neovascular AMD and central GA. Additionally, all our case definitions included a 
visual acuity of 20/30 or worse due primarily to AMD except for those neovascular AMD cases 
that had anti-VEGF therapy. The person was used as the unit of analysis, and the worst eye was 
used for classification.  
In 2010, we recontacted approximately 2,300 previous AMD patients in the NHS who had AMD 
signs (either met or unmet our case definitions at that time) to ascertain whether or not their 
AMD may have progressed. Those cases accrued by recontact questionnaires were not included 
in the main analysis due to evidence of reverse causation bias (e.g. patients increased dietary 
intakes of carotenoids after the initial diagnosis of AMD; see Results).  
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Dietary Assessment of Carotenoids 
We began follow up in 1984 for the NHS and 1986 for the HPFS, when the first comprehensive 
FFQ with an expanded section on fruit and vegetable intake was administered, and updated 
dietary intake every four years. On the FFQs, commonly used units or portion sizes (e.g., 1 
orange or ½ cup broccoli) are specified for each item. The FFQs contained at least 15 questions 
for fruit and juice intake and 30 questions for vegetable intake. Participants were asked to report 
how often, on average over the past year, they had consumed each food item (responses ranging 
from “≤1 time per month” to “≥6 times/day”). Use and dosage of β-carotene and multivitamin 
supplements was assessed by biennial questionnaires with additional information on brands for 
multivitamins, whereas lycopene supplements were only inquired about from 2002 onwards. We 
calculated nutrient intakes by multiplying the consumption frequency of each food by the 
nutrient content of the specified food portion summing across all foods. Nutrient values were 
energy-adjusted using the residual method.
25
 The FFQ has been validated in both cohorts and 
had good reproducibility and validity in measuring a wide range of foods and nutrients.
26-30
  
Because of variation in assessment validity and bioavailability across carotenoid-containing 
foods, calculated intakes of carotenoids from FFQs may not adequately represent the more 
biologically relevant internal dosage. We thus utilized a previously validated empirical 
prediction model among 4,180 nonsmoking women in the NHS that related carotenoid-
containing foods directly to the measured plasma carotenoid level using linear regression.
31
 We 
made two changes to the original prediction model: 1) we excluded cucumber from the 
prediction model of β-cryptoxanthin because it was only asked in the 1986 FFQ; 2) we further 
developed a prediction model for food-sourced β-carotene by excluding β-carotene supplement 
users in 1990. The final prediction models used in this paper were shown in Supplementary 
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Table 1.1. The regression coefficient of each food in the model reflected a weighted contribution 
to the bioavailable level. We then derived predicted plasma carotenoid scores for all participants 
by multiplying the consumption frequency of each food by its regression coefficient and 
summing across all foods. We created a total carotenoid index by first categorizing each 
predicted plasma score into quintiles and then summing the quintile scores across all carotenoids 
yielding a final score ranging from 5 to 25. The empirical prediction model demonstrated 
improved assessment of carotenoid intakes compared to conventional food composition based 
method.
31
  
Statistical Analysis 
Main Analysis 
We calculated the cumulative average for predicted plasma carotenoid scores by averaging 
scores from all available FFQs up to the start of each two-year risk interval. We used time-
varying multivariate Cox proportional hazards model to estimate the hazard ratios (HR) and 95% 
confidence intervals controlling for known and suspected risk factors. We assessed the linear 
trend across categories by modeling the median level of each category as a continuous variable. 
We examined the possible non-linear relations between carotenoids and AMD non-
parametrically by the likelihood ratio test comparing a model with only the linear term to a 
model with the linear and restricted cubic splines with four knots.
32
  
To assess whether the associations between carotenoids and AMD would vary by prespecified 
risk factors including age, BMI, smoking status, and postmenopausal hormone use, we created 
interaction terms between carotenoids and these variables and tested their significance using 
likelihood ratio tests. In exploratory analysis, we investigated the independent association of 
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each carotenoid adjusting for all other carotenoids as a composite variable (sum of the quintile 
score of each carotenoid).  
We performed the analyses separately in each cohort and pooled the results with an inverse 
variance-weighted meta-analysis using the fixed-effects model. We used an α- level of 0.05 
without adjustment for multiple comparisons. SAS was used to perform the analyses (SAS 9.3, 
SAS Institute, Cary, NC). 
Recontact Analysis in the NHS 
To assess whether among recontacted patients an initial diagnosis of AMD was associated with 
change in dietary intakes of carotenoids, we followed the method that has been outlined in the 
study by Bernstein et al.
33
 Briefly, we fit a generalized linear model accounting for within-person 
repeated dietary measures as below. 
Change in calorie-adjusted carotenoid intake = β1 (time interval) + β2 (AMD) + β3 (time interval 
X AMD) + β4 (total calories) 
Change in calorie-adjusted carotenoid intake = for example, change in calorie-adjusted 
carotenoid intake in 1986 was the calorie-adjusted intake in 1984 subtracted from the calorie-
adjusted intake in 1990 
Time interval=Time interval-7, centered at the 7
th
 interval for model interpretability; 13 intervals 
ranged from 1984 to 2010  
β1= Change in calorie-adjusted carotenoid intake per 1 interval increase in non AMD participants 
β2= Change in calorie-adjusted carotenoid intake associated with a diagnosis of AMD during the 
middle of follow-up 
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β3= Difference in the rate of change in calorie-adjusted carotenoid intake comparing AMD 
patients to non-AMD participants (of the most interest) 
We compared the results from main follow-up with the results from main follow-up plus 
recontact to assess the degree of reverse causation bias. To control for this bias in the analysis 
including recontacted cases, we first attempted stopping updating the patient’s diet after the first 
diagnosis of AMD and carried forward the diet before the diagnosis throughout the rest of 
follow-up. However, because stop updating diet may lead to misclassification especially when 
there is a temporal trend in carotenoid intake, we created z-scores of carotenoid intake during 
each follow-up cycle by subtracting the population’s mean carotenoid intake from each 
participant’s own intake and then divided by the population mean’s standard deviation. We 
stopped updating a participant’s z-score upon the first diagnosis of AMD. 
III. Results 
Main Analysis 
During 26 years of follow-up in the NHS and 24 years in the HPFS, we confirmed 1,361 incident 
intermediate and 1,118 advanced AMD cases (>96% neovascular AMD). The median age of 
AMD onset was 73 years in women and 76 years in men.  
In 1996 (the middle of follow-up), participants at the highest cumulative average predicted 
plasma score of lutein/zeaxanthin were likely to be more physically active, smoke less, consume 
more fruits and vegetables and score higher in aHEI. They also had higher calculated intakes of 
lutein/zeaxanthin and other carotenoids (Table 1.1).  
Predicted plasma carotenoid scores were strongly correlated with their respective calculated 
intakes (Spearman correlation, r = 0.67 to 0.90), and with each other (e.g., r=0.64 between 
 11 
 
lutein/zeaxanthin and food-sourced β-carotene, r=0.67 between α-carotene and food-sourced β-
carotene). Lycopene had the weakest correlations with all other carotenoids (r ≤ 0.18).  
We identified an inverse association with advanced AMD for predicted plasma carotenoid scores 
of: lutein/zeaxanthin, β-cryptoxanthin, α-carotene, food-sourced β-carotene, total carotene and 
total carotenoid index (Table 1.2). Predicted plasma lutein/zeaxanthin score and total carotenoid 
index had a linear relationship with advanced AMD within the range of dietary intake (Figure 
1.1). Carotenoids other than lycopene had a similar linear relation (all p for linearity < 0.05; all p 
for non-linearity > 0.10; graphs not shown). For the outcome of intermediate AMD, we did not 
observe any association for any predicted plasma carotenoid scores (Table 1.2). The results did 
not materially change when restricted to a subgroup of intermediate AMD with large drusen or 
non-central GA (283 in the NHS and 80 in the HPFS; data not shown). 
Because AREDS2 raised the concern for the competitive absorption between lutein/zeaxanthin 
and β-carotene, in a sensitivity analysis we excluded β-carotene supplement users (4.5% of the 
person-years in the NHS and 10% in the HPFS) from the analysis of predicted plasma 
lutein/zeaxanthin score. However, neither the HR for advanced AMD (HR=0.58; 95% 
confidence interval (CI): 0.47 – 0.72; p for trend, < 0.001) nor the HR for intermediate AMD 
(HR=0.90; 95% CI: 0.75 – 1.09; p for trend, 0.26) was essentially altered.  
In secondary analyses using calculated intakes of carotenoids, lutein/zeaxanthin, β-cryptoxanthin, 
α-carotene and food-sourced β-carotene were also inversely related to advanced AMD in the 
NHS (Supplementary Table 1.2); However, none of them was associated with advanced AMD in 
the HPFS (Supplementary Table 1.3).  
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The primary food sources for measured plasma carotenoid levels in the NHS
31
 were cooked and 
raw spinach for lutein/zeaxanthin, oranges and orange juice for β-cryptoxanthin, cooked and raw 
carrots for both α- and β-carotene, and tomato sauce for lycopene (Figure 1.2), consistent with 
NHANES.
34
  These foods were generally inversely related to advanced AMD, although with 
variation for specific forms of these foods (Figure 1.2). The inverse association between tomato 
sauce and advanced AMD was primarily attributed to that in the HPFS (HPFS, HR comparing ≥ 
2 servings/wk to almost never = 0.60; 95% CI = 0.39 – 0.93; p for trend, 0.01). Cooked spinach 
and orange juice had an inverse association with intermediate AMD. Although not the primary 
source of α-carotene,  bananas, which predicted plasma α-carotene level in our sample, was 
inversely relate to intermediate AMD (HR comparing ≥ 5 pieces/wk to almost never = 0.83; 95% 
CI= 0.70-1.00; p for trend, 0.003). 
In an exploratory analysis adjusted for all other carotenoids as a composite score, only 
lutein/zeaxanthin and α-carotene persisted with an inverse association with advanced AMD 
(Figure 1.3). β-cryptoxanthin, β-carotene and lycopene collectively did not have an inverse 
association after accounting for lutein/zeaxanthin and α-carotene; nor did β-cryptoxanthin and β-
carotene combined after accounting for all other carotenoids. In the sensitivity analysis in which 
we entered each individual carotenoid in the same model, the inverse association for 
lutein/zeaxanthin and α-carotene persisted (lutein/zeaxanthin, HR= 0.66, 95% CI= 0.50 to 0.87; 
α-carotene, HR= 0.75, 95% CI= 0.59 to 0.96). 
Plasma carotenoid scores except lycopene seemed to be associated with a lower risk of total 
AMD among postmenopausal women currently using exogenous hormones compared to those 
not currently using (Supplementary Figure 1.1).We also found a suggestive stronger inverse 
association for all predicted plasma carotenoid scores except lycopene with advanced AMD in 
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those 75 years and older and this was most pronounced for lutein/zeaxanthin (p for interaction, 
0.04) (Supplementary Figure 1.2 A). We found similar HRs in never compared to ever smokers 
(all p for interaction > 0.25) (Supplementary Figure 1.2 B).  
Recontact Analysis in the NHS 
Among all those who had responded to our recontact questionnaires, 558 patients met our case 
definition including 300 intermediate and 258 advanced AMD cases. Among them, 422 patients’ 
AMD status progressed after the first diagnosis; the median time to AMD progression was 5.7 
years (IQR: 1.7 – 10.3). From the date of initial diagnosis to the date of progression, 
lutein/zeaxanthin intake has significantly increased compared to those who did not have AMD 
during the same period (Supplementary Table 1.4). When stratified by the case status at the time 
of recontact, advanced AMD patients increased the intake of lutein/zeaxanthin more than 
intermediate AMD patients. There were no significant changes of intakes for other carotenoids.  
After adding recontacted cases, 1,043 intermediate and1,002 advanced AMD cases were 
included in the analysis in comparison with 983 intermediate and 773 advanced AMD cases in 
the main follow-up. The associations of all predicted carotenoid scores (except for lycopene) 
with advanced AMD were slightly attenuated (Supplementary Figure 1.3). Neither stopping 
updating the diet after the date of initial diagnosis of AMD nor further using z-score to account 
for possible temporal trends of carotenoid intakes materially deattenuated the associations. On 
the other hand, the associations of all predicted carotenoid scores with intermediate AMD were 
still null across 4 analytical methods (Supplementary Figure 1.3).  
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Because statistical methods were unable to fully control for the reverse causation bias possibly 
due to the fact that AMD patients may have varying degree of diet change depending on initial 
disease severity, we decided not to include recontacted AMD cases in the main analysis. 
IV. Discussion 
Our findings from two large, long-running prospective cohorts with repeated dietary assessments 
suggest that a higher intake of bioavailable lutein/zeaxanthin is associated with a 40% lower risk 
of advanced AMD. Higher intakes of other bioavailable carotenoids also contribute to a reduced 
risk of advanced AMD. In contrast, intakes of carotenoids were not associated with intermediate 
AMD, suggesting an effect on AMD progression rather than initiation. 
Although the inverse association between lutein/zeaxanthin and advanced AMD was consistent 
with a number of previous studies,
12,13,19-21,35
 the observational nature of our study precludes the 
level of causal inference that could be derived from a randomized trial. Unfortunately, the 
primary analyses of the AREDS 2 trial failed to prove a protective effect of lutein/zeaxanthin.
16
 
However, when restricted to participants at the bottom 20% of dietary intake of lutein/zeaxanthin, 
there was a 26% risk reduction.
17
 The subgroup result is consistent with the hypothesis that 
supplements may be more effective when the background dietary intake is below a biologically 
sufficient threshold. Given the unlikely occurrence of another well-designed large-scale 
randomized trial, long-running large prospective cohort studies like ours provide the best 
available evidence to further strengthen the evidence base for a protective role of 
lutein/zeaxanthin. 
Lutein and zeaxanthin form macular pigments that may protect against AMD by reducing 
oxidative stress, absorbing blue light and stabilizing cell membranes.
11
 Cross- sectional 
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(reviewed in Beatty et al
36
) and experimental studies
37-39
 have shown a significant correlation 
between serum lutein and zeaxanthin and macular pigment optical density (MPOD). Increasing 
evidence also suggests that genetic variants related to lutein and zeaxanthin metabolism are 
associated with MPOD or AMD.
40-43
 Therefore, multiple independent lines of evidence all point 
to a protective role of lutein and zeaxanthin in the development of advanced AMD.  
Several mechanisms could explain the protective roles of other carotenoids including α-carotene, 
β-carotene and β-cryptoxanthin, those non-macular pigment carotenoids. All carotenoids are 
potent antioxidants, which could reduce systematic oxidative stress that indirectly influences the 
macula. The original AREDS formula containing β-carotene, antioxidant vitamins and minerals 
but not lutein and zeaxanthin reduced the risk of AMD progression by a quarter.
44
 Carotenoids 
including α-carotene, β-carotene and lycopene have been found in human RPE/choroid,18 and 
could protect this tissue against light-induced oxidative damage and locally produced free 
radicals. The integrity of RPE/choroid could further impact the uptake of lutein/zeaxanthin by 
retina from the circulating blood. We also speculate that other carotenoids may directly protect 
lutein/zeaxanthin from oxidative damage in both blood and RPE/choroid. Among a subsample of 
women in the NHS, we found that measured plasma lutein/zeaxanthin could be significantly 
predicted by every other plasma carotenoid apart from its own food sources (all p<0.001), in 
accordance with a separate study.
45
  
We did not find an association between carotenoids and intermediate AMD. While one previous 
case-control study
13
 and one cross-sectional study
46
 reported an inverse association, only one
35
 of 
three prospective cohort studies
15,35,47
 reported a significant inverse association between intake of 
lutein/zeaxanthin and intermediate AMD. One nested case-control study based on 41 cases found 
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an inverse association for serum lutein/zeaxanthin but not for other carotenoids,
48
 whereas two 
other case-control studies
14,20
 only found an inverse association for serum lycopene.  
Our study has some limitations. Although our results did not appreciably change after adjusting 
for many known and suspected risk factors including aHEI, an indicator of a healthy dietary 
pattern,
49
 residual confounding from unaccounted or imprecise measurement cannot be excluded. 
However, similar associations among ever and never smokers assured us that results were 
unlikely to be confounded by smoking, the strongest modifiable risk factor for advanced AMD.
50
 
Because our nutrient and blood database assessed lutein and zeaxanthin together, we were unable 
to estimate the individual effect of each nutrient to inform the optimal ratio for supplementation. 
Although the relationship between lutein/zeaxanthin and advanced AMD was linear within the 
range consumed in our cohorts (0.8 - 10.7 mg/d), we could not evaluate the effect of the higher 
dosage (10 mg lutein plus 2 mg zeaxanthin) used in the AREDS2 formula. Some patients with 
intermediate AMD in the later follow-up may have been taking the AREDS formula, which was 
not ascertained by our FFQs and this may have resulted in underestimation of the true 
associations between carotenoids and advanced AMD because dietary effects of carotenoids 
could be masked under intake of pharmacological doses of antioxidant vitamins and minerals.  
Strengths of this study included a prospective cohort design with high follow-up that minimized 
recall and selection biases. Another strength lies in our creation of predicted plasma carotenoid 
scores to better estimate the true variation of carotenoid exposures accounting for variations in 
bioavailability across different foods,
51,52
 preparation methods,
53
 accuracy of responses to 
various FFQ items, and of food composition databases. Analyses using the predicted plasma 
scores strengthened the association between lutein/zeaxanthin and advanced AMD, and modestly 
improved associations with other carotenoids. Differences in the impact of substituting estimated 
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bioavailable nutrient levels among specific carotenoids might be attributable to variation in the 
accuracy of FFQ data for specific food items. The predicted plasma score for lutein/zeaxanthin 
(median, 16.9 μg/ dL) in our cohorts was comparable to the baseline serum level in AREDS2 
participants (mean, 17.9 μg/ dL) and the general population participants older than 60 years 
sampled from 2005-2006 NHANES (mean, 15.0 μg/ dL).16 
In conclusion, higher intakes of bioavailable carotenoids, particularly lutein/zeaxanthin and α-
carotene are associated with reduced risk of advanced AMD. This study lends further support to 
the causal role of lutein/zeaxanthin in protecting against the development of advanced AMD. 
Because other carotenoids may also have a protective role, a public health strategy of increasing 
the consumption of a wide variety of fruits and vegetables rich in carotenoids could be most 
beneficial and is compatible with current dietary guidelines.  
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VI. Tables and Figures 
Table 1.1. Age-standardized characteristics of participants in the NHS and HPFS 
according to the cumulative average predicted plasma score of lutein/zeaxanthin in 1996 
 
lutein/zeaxanthin, quintiles 
Characteristics Q1 Q2 Q3 Q4 Q5 
NHS 
     Participants, No. 10,548 10,548 10,548 10,548 10,548 
Age, mean, y 62 62 62 62 63 
BMI
¶
, mean, kg/m
2
 27 27 27 27 26 
White race, % 99 98 98 98 97 
Current smokers, % 17 13 10 9 8 
Pack years of smoking 29 25 23 21 20 
Physical activity, median, MET-h/wk 8 9 11 13 16 
Hypertension, % 39 41 41 41 38 
Postmenopausal, % 90 90 90 90 90 
Current menopausal hormone use
§
, % 37 41 42 43 44 
Current aspirin use, % 46 48 50 50 50 
Dietary intake, mean 
     Total energy intake, Kcal/d 1,703 1,670 1,698 1,756 1,877 
Alcohol, g/d 5 5 6 6 7 
Fruits and vegetables, servings/d 4 5 5 6 8 
aHEI 
(excluding fruits and vegetables) 
39 41 42 43 44 
Lutein/zeaxanthin, μg/d 1,657 2,259 2,732 3,338 4,779 
α-carotene, μg/d 528 662 767 873 1,112 
β-carotene, μg/d 2,890 4,690 4,324 5,101 6,862 
β-cryptoxanthin, μg/d 110 156 184 208 241 
Lycopene, μg/d 5,935 6,314 6,571 6,748 7,093 
ALA, g/d 0.93 0.95 0.96 0.98 1.01 
  DHA, g/d 0.11 0.13 0.14 0.16 0.19 
Predicted lutein/zeaxanthin  
plasma score, mean, μg/L 152 161 169 179 203 
HPFS 
     Participants, No. 4,999 4,999 5,000 4,999 4,999 
Age, mean, y 62 63 63 64 64 
BMI
¶
, mean, kg/m
2
 26 26 26 26 26 
White race, % 97 96 95 96 95 
Current smokers, % 8 5 4 4 4 
Pack years of smoking 14 13 12 12 11 
Physical activity, median, MET-h/wk 20 23 25 28 32 
Hypertension, % 34 34 34 33 34 
Current aspirin use, % 68 70 70 68 67 
Dietary intake, mean 
     Total energy intake, Kcal/d 2,068 1,938 1,956 1,998 2,115 
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Table 1.1. (Continued) Age-standardized characteristics of participants in the NHS and 
HPFS according to the cumulative average predicted plasma score of lutein/zeaxanthin in 
1996 
 lutein/zeaxanthin, quintiles 
Characteristics Q1 Q2 Q3 Q4 Q5 
Alcohol, g/d 12 11 11 11 11 
Fruits and vegetables, servings/d 4 5 6 6 8 
aHEI 
(excluding fruits and vegetables) 
41 43 44 45 47 
Lutein/zeaxanthin, μg/d 1,848 2,563 3,091 3,832 5,468 
α-carotene, μg/d 606 768 879 1,024 1,374 
β-carotene, μg/d 3,413 4,341 5,052 6,013 8,152 
β-cryptoxanthin, μg/d 121 172 211 244 307 
Lycopene, μg/d 6,545 7,223 7,532 7,888 8,520 
ALA, g/d 1.05 1.07 1.08 1.10 1.13 
DHA, g/d 0.16 0.19 0.20 0.23 0.27 
Predicted lutein/zeaxanthin  
plasma score, mean, μg/L 149 159 167 177 202 
Abbreviations: BMI, body mass index; MET-h, hours of metabolic equivalent tasks; aHEI, alternative 
healthy eating index; ALA, α-linolenic acid; DHA, docosahexaenoic acid. 
¶
BMI is calculated as weight in kilograms divided by height in meters squared.
  
§
Current menopausal hormone use among postmenopausal women. 
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Table 1.2. Pooled hazard ratios of AMD according to quintiles of predicted plasma 
carotenoid scores and calculated intakes in NHS and HPFS 
   Advanced AMD 
 
Intermediate AMD 
 
 Predicted 
Plasma Score 
 Calculated 
Intake
¶
  
Predicted 
Plasma Score 
 Calculated  
Intake
¶
 
Carotenoids  Multivariate HR (95% CI) 
Lutein/Zeaxanthin   
   
   
Q1  1(Ref.)  1(Ref.) 
 
1(Ref.)  1(Ref.) 
Q2  0.82 (0.68, 0.99)  0.90 (0.75, 1.08) 
 
0.97 (0.82, 1.15)  0.92 (0.78, 1.10) 
Q3   0.94 (0.78, 1.12)  0.86 (0.71, 1.03) 
 
0.95 (0.80, 1.13)  0.96 (0.81, 1.14) 
Q4  0.83 (0.69, 1.00)  0.81 (0.67, 0.99) 
 
0.93 (0.78, 1.11)  0.96 (0.80, 1.14) 
Q5   0.59 (0.48, 0.73)  0.79 (0.64, 0.97) 
 
0.93 (0.78, 1.12)  0.97 (0.81, 1.16) 
p for trend  <.001  0.04 
 
0.42  0.99 
p for heterogeneity  0.99  0.04 
 
0.92  0.17 
β-cryptoxanthin  
 
 
   
 
 
Q1  1(Ref.)  1(Ref.) 
 
1(Ref.)  1(Ref.) 
Q2  0.94 (0.78, 1.14)  0.83 (0.69, 1.01) 
 
0.87 (0.73, 1.04)  0.97 (0.81, 1.15) 
Q3  0.87 (0.72, 1.05)  0.86 (0.72, 1.04) 
 
1.00 (0.84, 1.18)  0.98 (0.82, 1.16) 
Q4  0.90 (0.74, 1.08)  0.84 (0.70, 1.02) 
 
0.91 (0.77, 1.09)  0.90 (0.75, 1.08) 
Q5  0.73 (0.60, 0.89)  0.71 (0.58, 0.86) 
 
0.85 (0.72, 1.02)  0.90 (0.75, 1.07) 
p for trend  0.002  0.002 
 
0.12  0.12 
p for heterogeneity  0.97  0.73 
 
0.20  0.13 
Lycopene  
 
 
   
 
 
Q1  1(Ref.)  1(Ref.) 
 
1(Ref.)  1(Ref.) 
Q2  0.98 (0.83, 1.16)  1.02 (0.86, 1.21) 
 
0.94 (0.81, 1.10)  0.98 (0.84, 1.15) 
Q3  0.93 (0.78, 1.11)  0.97 (0.81, 1.16) 
 
1.01 (0.86, 1.19)  0.98 (0.83, 1.15) 
Q4  0.85 (0.71, 1.03)  0.77 (0.63, 0.94) 
 
0.95 (0.80, 1.12)  1.04 (0.88, 1.23) 
Q5  0.93 (0.76, 1.13)  1.00 (0.83, 1.21) 
 
1.04 (0.87, 1.23)  1.05 (0.88, 1.24) 
p for trend  0.17  0.38 
 
0.64  0.44 
p for heterogeneity  0.08  0.59 
 
0.86  0.96 
α-carotene  
 
 
   
 
 
Q1  1(Ref.)  1(Ref.) 
 
1(Ref.)  1(Ref.) 
Q2  0.99 (0.82, 1.19)  0.81 (0.67, 0.98) 
 
0.88 (0.73, 1.04)  0.94 (0.78, 1.13) 
Q3  0.92 (0.76, 1.11)  0.82 (0.68, 0.99) 
 
0.91 (0.77, 1.08)  0.95 (0.79, 1.13) 
Q4  0.88 (0.73, 1.07)  0.82 (0.68, 0.99) 
 
0.87 (0.73, 1.04)  1.13 (0.95, 1.34) 
Q5  0.69 (0.56, 0.84)  0.68 (0.56, 0.83) 
 
0.94 (0.79, 1.12)  0.98 (0.82, 1.17) 
p for trend  <.001  0.002 
 
0.86  0.69 
p for heterogeneity  0.36  0.08 
 
0.68  0.24 
β-carotene  
 
 
   
 
 
Q1  1(Ref.)  1(Ref.) 
 
1(Ref.)  1(Ref.) 
Q2  0.97 (0.80, 1.17)  1.04 (0.86, 1.26) 
 
1.02 (0.85, 1.22)  0.99 (0.82, 1.18) 
Q3  0.90 (0.74, 1.09)  0.96 (0.79, 1.16) 
 
1.08 (0.90, 1.29)  1.09 (0.91, 1.30) 
Q4  0.80 (0.65, 0.97)  0.86 (0.70, 1.05) 
 
0.99 (0.82, 1.19)  1.02 (0.85, 1.23) 
Q5  0.82 (0.67, 1.01)  0.86 (0.69, 1.06) 
 
1.03 (0.85, 1.24)  0.99 (0.82, 1.20) 
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Table 1.2. (Continued) Pooled hazard ratios of AMD according to quintiles of predicted 
plasma carotenoid scores and calculated intakes in NHS and HPFS 
  Advanced AMD  Intermediate AMD 
 
 Predicted 
Plasma Score 
 Calculated 
Intake
¶
 
 
Predicted 
Plasma Score 
 Calculated  
Intake
¶
 
Carotenoids  Multivariate HR (95% CI) 
p for trend  0.03  0.05 
 
0.92  0.88 
p for heterogeneity  0.28  0.99 
 
0.87  0.65 
β-carotene from food  
   
 
 
Q1  1(Ref.)  1(Ref.) 
 
1(Ref.)  1(Ref.) 
Q2  0.84 (0.69, 1.02)  0.97 (0.80, 1.18) 
 
0.93 (0.77, 1.11)  0.86 (0.71, 1.03) 
Q3  0.80 (0.66, 0.97)  0.89 (0.73, 1.09) 
 
0.97 (0.80, 1.16)  0.96 (0.80, 1.15) 
Q4  0.79 (0.64, 0.96)  0.86 (0.70, 1.05) 
 
1.00 (0.83, 1.21)  1.01 (0.84, 1.21) 
Q5  0.64 (0.52, 0.79)  0.68 (0.55, 0.85) 
 
1.02 (0.84, 1.24)  0.92 (0.76, 1.12) 
p for trend  <.001  <.001 
 
0.47  0.88 
p for heterogeneity  0.67  0.60 
 
0.94  0.90 
Total carotene from food  
   
 
 
Q1  1(Ref.)  1(Ref.) 
 
1(Ref.)  1(Ref.) 
Q2  0.89 (0.74, 1.08)  0.97 (0.80, 1.17)  0.88 (0.73, 1.06) 
 0.87 (0.72, 1.05) 
Q3  0.76 (0.62, 0.93)  0.89 (0.74, 1.09)  0.95 (0.79, 1.14) 
 0.98 (0.82, 1.17) 
Q4  0.77 (0.63, 0.94)  0.78 (0.64, 0.95)  0.94 (0.78, 1.14) 
 0.96 (0.80, 1.16) 
Q5  0.64 (0.51, 0.79)  0.72 (0.58, 0.89)  0.99 (0.82, 1.19) 
 0.94 (0.78, 1.13) 
p for trend  <.001  <.001  
0.64  0.89 
p for heterogeneity  0.59  0.65 
 
0.96  0.40 
Total carotenoid index
§
  
   
 
 
Q1  1(Ref.)  1(Ref.) 
 
1(Ref.)  1(Ref.) 
Q2  0.95 (0.80, 1.14)  0.83 (0.69, 1.00) 
 
0.77 (0.64, 0.91)  0.95 (0.80, 1.13) 
Q3  0.84 (0.70, 1.01)  0.82 (0.68, 0.99) 
 
0.93 (0.79, 1.10)  0.97 (0.82, 1.15) 
Q4  0.77 (0.64, 0.94)  0.79 (0.65, 0.95) 
 
0.87 (0.73, 1.03)  1.06 (0.90, 1.26) 
Q5  0.65 (0.53, 0.80)  0.72 (0.59, 0.87) 
 
0.92 (0.77, 1.10)  0.99 (0.83, 1.18) 
p for trend  <.001  0.001  
0.80  0.73 
p for heterogeneity  0.67  0.51 
 
0.98  0.56 
Multivariate models were adjusted for: age (continuous), BMI (<18.5, 18.5-23, 23-25, 25-30, 30-35, ≥ 35 
kg/m2), pack-years of smoking (never, 1-9, 10-24, 25-44, 45-64, ≥65y), physical activity (<3, 3-8.9, 9-
17.9, 18-26.9, ≥27 MET-h/wk), current aspirin use (≥1 tablets/wk or none), history of hypertension, 
diabetes and cardiovascular diseases, dietary variables including aHEI (excluding fruits and vegetables), 
alcohol intake, DHA and ALA (all in quintiles). In NHS, models were additionally adjusted for 
postmenopausal status and menopausal hormone use (never, current and past); in HPFS additional 
adjustment for race (Caucasian v.s. non-Caucasian).                                                                                                                                                                             
§Total carotenoid index was created by summing the quintile score of each carotenoid. 
¶ Multivariate models were additionally adjusted for total calorie intake (in quintiles). 
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Figure 1.1. Dose-response relationship between predicted plasma carotenoid scores and the risk of advanced AMD 
 
 
Multivariate models were adjusted for: age (continuous), BMI (≥30 kg/m2), current aspirin use (≥1 tablets/wk), history of hypertension, pack-years 
of smoking, physical activity, and modified aHEI (all in categories). 
The solid lines represent the HRs and the dotted lines represent the 95% CIs.  
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Figure 1.2. Hazard ratios of AMD according to primary carotenoid-containing foods 
 
 
*, p for linear trend < 0.05; §, p for linear trend <0.10 
¶
, p for heterogeneity between NHS and HPFS <0.05 
ǂ
, Cooked spinach (1/2 cup) ≅ 2.5 * raw spinach (1 cup); Total spinach (1 cup) = raw spinach (1 cup) + 2.5* cooked spinach (1/2 cup). 
Multivariate models were adjusted for the same variables as in the Table 1.2. 
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Figure 1.3. Independent associations of predicted plasma carotenoid scores with advanced 
AMD  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                             HR comparing the top quintile to the bottom 
 
All other carotenoids were a composite score derived by totaling the quintile score of each carotenoid. 
p for heterogeneity between NHS and HFPS was > 0.10 for all the HRs. 
Multivariate models were adjusted for the same variables as in the Table 1.2.  
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ABSTRACT  
Objectives: To evaluate the associations between intake of eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) and the intermediate and advanced stages of AMD. 
Design: Prospective cohort study.  
Participants: 75,889 women from the Nurses’ Health Study and 38,961 men from the Health 
Professionals Follow-Up Study were followed from 1984 to 2012 and 1986 to 2010, respectively. 
At baseline all participants were free of diagnosed AMD and major chronic diseases (diabetes, 
cardiovascular disease and cancer) that may lead to a change of habitual diet.  
Methods: We assessed dietary intake by a validated food frequency questionnaire (FFQ) at 
baseline and every four years. We calculated cumulative average intake of EPA and DHA from 
FFQs and also computed predicted erythrocyte and plasma scores directly from food intake using 
regression models. Cox proportional hazards models were used to compute the associations with 
AMD outcomes. 
Main Outcome Measures: We confirmed 1,589 incident intermediate and 1,356 advanced 
AMD cases (primarily neovascular AMD) by medical record review. 
Results: For intermediate AMD, the pooled hazard ratio between the two cohorts for DHA 
comparing the extreme quintiles of intake was 0.78 (95% CI = 0.66 - 0.92; p trend = 0.008) and 
for EPA + DHA was 0.83 (95% CI = 0.71 - 0.98; p trend = 0.03). The pooled hazard ratio for 
fatty fish comparing ≥ 5 servings/wk to almost never was 0.61 (95% CI = 0.46 - 0.81; p trend < 
0.001). Secondary analyses using predicted erythrocyte and plasma scores of EPA and DHA 
 33 
 
yielded similar findings. For advanced AMD, we found no associations in the pooled analysis for 
either intake or predicted bioavailable levels. 
Conclusion: Higher intakes of EPA and DHA may prevent or delay the occurrence of visually 
significant intermediate AMD. However, the totality of current evidence for EPA and DHA and 
advanced AMD is discordant, though there was no association with advanced AMD in the 
present study. 
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I.  Introduction 
Age-related macular degeneration (AMD) is a chronic, degenerative disease of the macula, 
which can result in loss of the ability to read, write or drive.
1
 Although the advanced stages of 
AMD are often debilitating, some forms of advanced AMD can now be successfully managed 
with intravitreal injection of anti-VEGF agents, allowing patients to maintain or even restore 
vision for variable periods of time.
2-4
 On the other hand, although usually less visually 
debilitating, early/intermediate AMD affects a much larger number of persons worldwide, and 
increases risk of development of advanced AMD. According to the 2005-2008 US National 
Health and Nutrition Examination Survey (NHANES), the estimated prevalence in persons aged 
40 years and older was 5.7% for early/intermediate AMD versus 0.8% for advanced AMD.
5
 
Globally, among people of European ancestry, the prevalence was 11.2% for early/intermediate 
AMD versus 0.5% for advanced AMD.
6
 Although decreasing exposure to some risk factors (e.g. 
smoking and blood pressure) in recent years might eventually help mitigate the incidence of 
early/intermediate AMD,
5
 owing to rapidly aging populations and lack of other effective means 
of primary prevention, the number of early/intermediate AMD cases is expected to double in the 
next few decades.
6-8
 Therefore, identification of other means of primary prevention, especially 
for vision-threatening early/intermediate AMD cases, would carry marked public health 
significance. 
Docosahexaenoic acid (DHA), a long-chain omega3 (n3) fatty acid, is a major lipid component 
of retinal photoreceptor outer segment membranes that has anti-inflammation and anti-
angiogenesis properties that could protect against AMD.
9,10
 The retinal concentration of DHA is 
dependent upon and modifiable by diet.
11
 Eicosapentaenoic acid (EPA), although not 
concentrated in the retina, is a precursor to DHA, and its metabolites could similarly affect the 
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pathogenic processes of AMD.
9
 Our earlier study
12
 and investigations by others
13-15
 suggested 
that long-chain n3 fatty acids (DHA, EPA, and other 20 and 22-carbon n3 fatty acids) may 
reduce the risk of early/intermediate AMD. With respect to advanced AMD, intake of DHA was 
inversely associated with advanced AMD in several prospective cohort studies;
13,16-18
 but this 
finding was not corroborated by the Age-Related Eye Disease Study 2 (AREDS2) trial in which 
supplementation with DHA and EPA for 5 years did not slow the progression to advanced AMD 
among patients with intermediate AMD.
19
  
In light of the mixed findings from prior literature, we aimed to evaluate the relations of intakes 
of EPA and DHA to different stages of AMD in large prospective cohorts over 28 years of 
follow-up. 
II.  Methods 
Study Population 
The two large ongoing US prospective cohorts, the Nurses’ Health Study (NHS) and the Health 
Professionals Follow-up Study (HPFS), have been described in detail before.
20,21
 Briefly, the 
NHS includes 121,701 US female registered nurses aged 30 to 55 years in 1976. The HPFS 
includes 51,529 US male health professionals aged 40 to 75 years in 1986. Both cohorts are 
predominantly white (NHS: >98%; HPFS: >91%). The long-term follow-up rates are >95%. 
Questionnaires were mailed to all participants biennially to inquire updated lifestyle factors and 
disease outcomes. Food frequency questionnaires (FFQ’s) were mailed every four years to assess 
diet in the preceding year. Submission of a completed self-administered questionnaire was 
deemed to imply informed consent. The study protocol was approved by the Institutional Review 
Boards at the Brigham and Women's Hospital and Harvard T.H. Chan School of Public Health.  
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At study baseline (1984 in the NHS and 1986 in the HPFS), we excluded participants who did 
not return the initial FFQ, left more than 70 food items blank, reported implausible dietary intake 
(<600 or >3500 Kcal/d for the NHS and <800 or > 4200 Kcal/d for the HPFS), had prevalent 
AMD, or serious chronic diseases including cancer (except nonmelanoma skin cancer), diabetes 
and cardiovascular disease. To minimize detection bias, we also excluded participants who never 
reported an eye exam over the entire follow-up and excluded from analysis the person-time 
during any two-year interval in which a participant did not report an eye exam. Results did not 
materially change in sensitivity analyses including intervals lacking an eye exam. Participants 
were included in the analysis when ≥ 50 years old, and were censored at age 90 to alleviate 
concerns of low reporting validity (NHS, n=15; HPFS, n=528). By the end of follow-up, a total 
of 75,889 women and 38,961 men contributed to the analysis. 
AMD Ascertainment 
Our case definition has been previously validated by comparison with retinal images  and 
medical records.
22
 When a participant reported a diagnosis of AMD on a biennial questionnaire, 
we requested informed consent and then contacted the participant’s eye doctor to confirm the 
diagnosis by review of medical records. Cases with only small hard drusen (< 63μm diameter) 
were excluded. We defined intermediate AMD as having at least one of the following signs: 
intermediate drusen (≥ 63 and <125 µm), pigment abnormalities, large drusen (≥ 125 µm) or any 
non-central geographic atrophy (GA). We defined neovascular AMD as having any of the 
following: RPE detachment, subretinal neovascular membrane, disciform scar, or history of 
treatment with laser, photodynamic, or anti-VEGF therapies for AMD. Central GA was defined 
as having a central geographic atrophy lesion involving the center of the macula. Advanced 
AMD included neovascular AMD and central GA. Additionally, all case definitions, except 
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those recent neovascular AMD cases that had anti-VEGF therapies, included a visual acuity of 
20/30 or worse due primarily to AMD. This magnitude of vision loss is not only of clinical 
significance, but also is severe enough to warrant medical attention so as to minimize potential 
detection bias arising from differential health consciousness. The person was used as the unit of 
analysis, and the worst eye was used for classification.  
Dietary Assessment 
We began follow up in 1984 for the NHS and 1986 for the HPFS, when the first comprehensive 
FFQ with an expanded section on fish was administered, and assessed dietary intake every four 
years thereafter. FFQ items on fish or seafood consumption includes 1) canned tuna (3-4 oz); 2) 
dark meat fish (3-5 oz); 3) other fish (mainly white fish, 3-5 oz); 4) shrimp, lobster or scallops as 
main dish (3-5 oz). On the FFQs, commonly used units or portion sizes (e.g., 1 orange or ½ cup 
broccoli) are specified for the approximately 130 items. Participants were asked to report how 
often, on average over the past year, they had consumed each food item (responses ranging from 
“≤1 time per month” to “≥6 times/day”). Fish oil supplements including marine and cod liver oils 
were assessed from 1990 in the NHS and 1988 in the HPFS. We calculated nutrient intakes by 
multiplying the consumption frequency of each food by the nutrient content of the specified food 
portion summing across all foods. The nutrient composition data were primarily based on the US 
Department of Agriculture Nutrient Database supplemented with information from 
manufacturers and published reports. Nutrient values were energy-adjusted using the residual 
method.
23
  
The validity and reproducibility of FFQs in measuring polyunsaturated fatty acids and fish intake 
has been assessed in a random sample of 118 HPFS participants who completed two consecutive 
 38 
 
FFQs (1986 & 1987), two 1-week dietary records ~ 7 months apart and provided subcutaneous 
fat samples.
24
 The correlation was 0.61 for fish between two FFQs.
25
 The correlation between 
energy-adjusted EPA from FFQs and percentage of EPA in the adipose tissue was 0.47.
24
 An 
earlier validation study in the NHS cohort had similar findings.
26,27
  
Measurement of Erythrocyte and Plasma EPA and DHA  
Measurement error in FFQs and imprecision in the nutrient composition database may introduce 
error into the calculated intake of EPA and DHA. Because erythrocyte and plasma EPA and 
DHA reflect long-term dietary intake,
28
 we used an empirical prediction model to predict the 
erythrocyte and plasma levels of EPA and DHA directly from food intake based on previous 
blood measurements among participants of nested case-control studies of cardiovascular disease 
in the NHS and HPFS. We included all the cases and controls because all were free of disease at 
the time of blood collection. The details on blood collection and measurements have been 
described previously.
28,29
 Briefly, we collected whole blood samples from 32,826 women 
between 1989 and 1990 and from 18,225 men between 1993 and 1995. Risk set sampling was 
used to select 1-2 controls for each confirmed cases matched on age (within 2 years), time of 
blood donation, and other factors (e.g. smoking and fasting status) from 1990 to 2006 in the NHS 
and 1994 to 2004 in the HPFS.  
Statistical Analysis 
Participants contributed person-time to the analysis from the return of the baseline questionnaire 
if over age 50 years at baseline or from reaching 50 years old to the confirmed diagnosis of 
AMD, death, loss to follow-up or the end of follow-up (05/31/2012 for the NHS and 01/31/2010 
for the HPFS), whichever occurred first. To best represent long-term intake and minimize 
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measurement error,
30
 we calculated the cumulative average of intakes of EPA and DHA.  All 
cumulative averages were categorized into quintiles based on the distribution in each cohort.  
We used time-varying Cox proportional hazards model to estimate the hazard ratio (HR) and 95% 
confidence interval (CI) controlling for known and suspected risk factors, including race, body 
mass index (BMI), pack-years of smoking, physical activity, aspirin use, history of hypertension, 
history of hypercholesterolemia, menopausal status and postmenopausal hormone use (in the 
NHS only), and the alternative Healthy Eating Index 
31
 (aHEI, modified by excluding EPA + 
DHA) to account for confounding by healthy dietary pattern. We further adjusted for α-linoleic 
acid (ALA), the 18-carbon n3 fatty acid that was positively associated with AMD in our 
cohorts.
12
 We also tested whether the associations would vary by intake of linoleic acid (LA), an 
omega6 fatty acid, and by age. We created binary variables using the median intake of LA in 
each cohort, and the median age of onset of AMD cases (73 years old). We created the 
interaction terms and used a likelihood ratio test to test the significance of interactions by 
comparing models with and without the interaction terms. 
The empirical prediction model has been described previously.
32
 Briefly, among food sources of 
EPA and DHA, we used stepwise linear regression to select foods that were significantly 
predictive of EPA and DHA blood measurements (p < 0.05). We used the average of food intake 
between 1986 and 1990 FFQs in the NHS and between 1990 and 1994 FFQs in the HPFS to 
correspond with the time of blood draw and to reduce within-person variation. The prediction 
models were separately created in each cohort. We specifically excluded fish oil supplement 
users so that the predicted blood scores, when extended to all cohort participants, would more 
accurately reflect long-term dietary intake because intake of fish oil supplements during the 
follow-up was intermittent (only 4% participants in each cohort had a consistent intake for ≥ 4 
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years). We then computed predicted scores based on food intake from the FFQ at each 4-year 
cycle for the full cohorts and used the cumulative average values in the analysis. 
We performed the analyses separately in each cohort using SAS 9.3. To derive a pooled HR, we 
first combined the two cohorts and then used a Cox proportional hazards model in the pooled 
data stratified by the cohort. Interpretation of the results was mainly based on pooled HRs unless 
otherwise specified. All hypothesis tests were two-sided and used an α-value of 0.05.  
III.  Results 
In 1998 (the middle of follow-up), participants at the highest cumulative average intake of EPA 
+ DHA were likely to be more physically active, smoke less and consume a healthier diet. 
However, they were more likely to have a history of hypertension and hypercholesterolemia 
(Table 2.1).   
Intakes of EPA and DHA were strongly correlated (Pearson r=0.88). During the follow-up, 
intake of food-sourced EPA + DHA declined slightly (and the same for fatty fish), whereas the 
intake of fish oil supplements increased markedly especially after 2002 (Figure 2.1).  
1,589 intermediate AMD cases (1,209 in the NHS and 380 in the HPFS) and 1,356 advanced 
cases (1,010 in the NHS and 346 in the HPFS) were included in the analysis, and 96% of the 
advanced AMD cases were neovascular types. In pooled primary analysis (Table 2.2), the HR 
comparing extreme quintiles of intake of EPA + DHA for risk of intermediate AMD was 0.83 
(95% CI = 0.71 – 0.89; p trend = 0.03) but the inverse association was primarily attributable to 
DHA (HR=0.78; 95% CI = 0.66 – 0.92; p trend=0.008). Results excluding fish oil supplement 
users were similar. With respect to advanced AMD, we did not find any associations in the 
pooled analysis, with the exception of a significant inverse association in the HPFS for intake of 
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EPA + DHA when excluding fish oil supplement users. The results for advanced AMD were not 
materially altered in sensitivity analyses excluding African American participants, as they 
generally have a lower risk of AMD,
1,33,34
 as well as in analyses using deciles of intake (data not 
shown).  
We further examined associations between more remote dietary intake with AMD using the 
average of the first two FFQs in case an association with AMD would be missed if there was a 
long latency period between the intake and AMD onset. However, remote intakes of EPA and 
DHA were not associated with either intermediate or advanced AMD (data not shown). 
Supplementary Table 2.1 provides the empirical prediction models used for computing predicted 
erythrocyte and plasma scores of EPA and DHA for all cohort participants. The Spearman 
correlations between predicted blood scores and measured blood levels ranged from 0.21 to 0.56 
with stronger correlations for DHA and for measurements in the HPFS (Supplementary Table 
2.2). Among non-users of fish oil supplements, the pooled HRs of intermediate AMD for DHA 
were similar across analyses based on diet, predicted erythrocyte and plasma scores; the 
associations for EPA were strengthened when using predicted erythrocyte and plasma scores 
(Figure 2.2). With respect to advanced AMD, although the pooled HRs were similar across 
analyses, we observed significant heterogeneity between the HRs in the NHS and HPFS. In the 
HPFS, there were significant inverse associations for predicted erythrocyte and plasma scores of 
EPA and DHA with advanced AMD (Supplementary Table 2.3). 
Intake of total fatty fish was significantly inversely related to intermediate AMD (p for trend 
across intake categories < 0.001); the association was primarily attributed to canned tuna (Table 
2.3), for which the median intake was 3.5 times that of dark oily fish. In contrast, intake of other 
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fish (mainly white fish) was not associated with the risk of intermediate AMD. We did not find 
any significant association between any type of fish and advanced AMD.  
Two percent of the population in each cohort had a consistent intake of fish oil supplements for ≥ 
6 years. In terms of intermediate AMD, in the NHS after controlling for food-sourced intake of 
EPA + DHA and other risk factors, those consistent users compared to irregular users  and non-
users had a 40% (HR = 0.60; 95% CI = 0.36 – 1.01; p = 0.05) lower risk. When further 
restricting the comparison to consistent versus irregular users, the risk reduction was 45% (HR = 
0.55; 95% CI = 0.32 – 0.93; p = 0.02). With respect to advanced AMD, in the NHS consistent 
users compared to irregular users did not have a reduced risk (HR = 1.07; 95% CI = 0.73 – 1.58). 
In contrast, there were no significant associations in the HPFS between fish oil supplements and 
any type of AMD, but the 95% CIs surrounding the HRs were wide (e.g. for intermediate AMD 
comparing consistent to irregular users, HR = 0.95; 95% CI = 0.45 – 1.98; p = 0.88; other data 
not shown). 
High intake of n6 fatty acids is hypothesized to negate the inverse associations for long-chain n3 
fatty acids due to competition for the same enzymes.
16,35,36
 To explore this possibility, we 
stratified the analyses by the median intake level of linoleic acid, a major omega6 fatty acid. We 
did not find any statistically significant interactions in the pooled analysis (Supplementary Table 
2.4). We also did not find any significant interactions by age, although the HRs between DHA 
and intermediate AMD seemed to be lower in younger people in the NHS but had an opposite 
pattern in the HPFS (Supplementary Table 2.5). 
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IV.  Discussion 
In this large prospective study with 24-28 years of follow-up, high intake of DHA + EPA 
(especially DHA) and fatty fish, was associated with a 17 to 40% lower risk of visually 
significant intermediate AMD, but no reduction in the risk of advanced AMD. Results based on 
predicted erythrocyte and plasma DHA and EPA scores supported observations based on dietary 
intake. Overall, these data support the hypothesis that DHA and EPA may prevent or delay the 
onset of AMD. 
Among existing studies on the relation between intake of long-chain n3 fatty acids or fish with 
early/intermediate AMD, , two
37,38
 out of four cross-sectional studies
37-40
 reported an inverse 
association whereas 1 case-control study did not.
41
 In all 3 prospective cohort studies an inverse 
association was found.
13-15
 In particular, the 10-year prospective Women’s Health Study, which 
has a similar study methodology to ours (e.g. a cohort of female health professionals, the same 
Willett FFQs and classification of AMD types)
14
 showed similar results. Ours is the only study 
that has further explored and showed an inverse association for a consistent intake of fish oil 
supplements, although the HR was only significant in the NHS. A much smaller number of cases 
in the HPFS may have resulted in an inadequate power to detect an association; the wide CI for 
the HR in the HPFS did include the point estimate in the NHS.   
With respect to advanced AMD, an apparent discrepancy exists between observational studies 
across several populations and randomized trials. Observational studies
13,16-18,35-39
 were almost 
all suggestive of an inverse association, including four prospective cohort studies,
13,16-18
 two 
case-control studies,
35,36
 and two 
38,39
 out of three cross-sectional studies
37-39
. Two cross-
sectional studies based on erythrocyte or plasma EPA and DHA among a French population also 
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suggested an inverse association.
42,43
 In contrast, in two double-blinded, placebo-controlled, 
randomized trials, AREDS2 from US
19
 and NAT2 from France,
44
 supplementation of high dose 
EPA and DHA did not reduce the risk of progression to advanced AMD over 3-5 years of 
follow-up. While confounding may cause the inverse associations in observational studies, 
several other reasons could explain the null findings in randomized trials, including insufficient 
dosage, short duration of follow-up, timing of interventions that did not encompass the true latent 
period, poor compliance (NAT2 trial), a high baseline intakes of EPA and DHA, etc. In this 
study, although the associations with advanced AMD were null in the pooled analysis, in the 
HPFS we found significant inverse associations especially when using the predicted biomarker 
scores. The correlations between calculated intakes of EPA and DHA and measured blood levels 
were stronger in the HPFS than in the NHS perhaps due to a higher intake of fatty fish in the 
HPFS. However, the possibility of a chance finding cannot be excluded due to a much smaller 
number of advanced cases in the HPFS. Therefore, totaling all of existing evidence, the 
associations between intakes of EPA and DHA with advanced AMD remain unclear. 
Intuitively, a reduction in the incidence of intermediate AMD with EPA and DHA could 
ultimately decrease that of advanced AMD. However, AMD is a complex disease with different 
clinical manifestations and underlying genetic profiles.
45-47
 Clinically-defined intermediate AMD 
cases could harbor different underlying genetic backgrounds with different propensities for 
progression. Our AMD ascertainment scheme may have accrued mostly those intermediate AMD 
cases those that were slow progressing or not destined to progress further. The existence of this 
subset of intermediate AMD cases is plausible in view of: 1) the high prevalence of intermediate 
AMD (>20%) at older ages in white populations;
5,7,48
 2) the relatively small proportion of 
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intermediate AMD that progresses (18% progression rate over 5 years in the AREDS study
49
 and 
16% over 20 years by our estimation in the Beaver Dam Eye Study
48
). 
Multiple biological mechanisms by which EPA and DHA could affect the development of AMD 
have been proposed.
9
 Briefly, EPA and DHA may modulate the immune and inflammatory 
processes implicated in the pathogenesis of AMD by influencing gene expression, cell 
differentiation and survival either through affecting cell membrane function or interceding 
cellular signaling cascades.
9
 The metabolites of EPA and DHA, eicosanoids, are also known as 
potent regulators of immune and inflammatory responses.
50,51
  
Our study has several strengths and limitations. The prospective design and high follow-up rate 
minimized the likelihood of recall and selection bias, respectively. To our knowledge, this is the 
only observational study that has repeated dietary assessment, which not only dampens within-
person variation but also reflects dietary change over time. Also to our knowledge, we are the 
first study to make use of food intake and existing blood data to develop predicted blood scores 
for AMD research. The empirical prediction model provides an alternative way of estimating 
exposure that accounts for the variation in accuracy across self-reported foods, imprecision in 
food composition database and variation in absorption and metabolism. Consistent findings 
between blood and dietary analyses lend support to the validity of our results. The observational 
design cannot exclude residual or unmeasured confounding, but this is unlikely to have a major 
impact on the current results, as the HRs did not appreciably change after extensive adjustment 
for known and suspected risk factors. To rule out the possibility that high intake of EPA and 
DHA is a marker for healthy dietary pattern, we specifically adjusted for a recognized indicator 
of diet quality,
31
 and the results were essentially the same pre and post-adjustment. EPA and 
DHA could also be a marker for other beneficial components of fatty fish, e.g. vitamin D, but the 
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suggestive inverse association also seen for fish oil supplements is consistent with the hypothesis 
that the primary causal factors are EPA and DHA. Another issue of concern is that participants at 
the high intake of EPA and DHA were more likely to be health-conscious and to have an eye 
exam, and thus to have existing AMD diagnosed. This could result in detection bias that may 
particularly affect early/intermediate AMD, which is usually asymptomatic, and may lead to an 
underestimation of a true benefit. To minimize the effect of such bias, we restricted to those 
AMD cases that were sufficiently visually significant to warrant medical attention and also 
excluded those who did not report an eye exam in the past 2 years.  
In summary, this prospective study over more than two decades of follow-up supports beneficial 
effects of EPA and DHA on the risk of visually significant intermediate AMD. Specifically, 
intake of EPA + DHA ≥ 350 mg/d or fatty fish starting from ≥ 2 servings/week may provide a 
moderate reduction in risk. Given that less than 5% of US adults and fewer than 1 in 4 adults 
consumed that amount of EPA + DHA and fatty fish, respectively, according to 2009 – 2010 
NHANES,
52
 increasing the average intake on a population basis may have implications for the 
primary prevention of visually significant intermediate AMD. Consistent long-term intake of fish 
oil supplements, which on average contain 590 mg of EPA + DHA,
53
 may be an appealing 
alternative to achieve the same benefit. Whether intakes of EPA and DHA may protect against 
the development of advanced AMD is still inconclusive but current evidence does not suggest 
any harm.
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VI.  Tables and Figures  
Table 2.1. Age-standardized characteristics of participants according to cumulative 
average intake of EPA + DHA in 1998 (middle of follow-up) 
 
EPA + DHA (diet + supplements), Quintiles 
 
Q1 Q2 Q3 Q4 Q5 
NHS 
     
Participants, No. 13,329 13,198 13,268 13,208 13,267 
Age, y 63 63 64 64 64 
¶
BMI, kg/m
2
 26.5 26.6 26.8 26.8 26.8 
Caucasians, % 98 98 98 97 96 
Current smokers, % 12 11 10 9 8 
Pack years of smoking 27 25 24 23 22 
Physical activity, MET-h/wk 15 16 17 19 21 
Hypertension, % 42 43 43 45 46 
Hypercholesterolemia, % 54 56 57 59 60 
Postmenopausal, % 94 94 94 94 94 
§
Current menopausal hormone use, % 42 44 46 46 46 
Current aspirin use, % 44 48 50 50 50 
Fish oil supplements, % 0 0 1 3 12 
Dietary intake 
     
ALA, mg/d 956 962 961 963 978 
EPA + DHA, mg/d 67 123 174 240 416 
LA, g/d 9 9 9 9 9 
Fruits and vegetables, servings/d 5 5 6 6 6 
Red meat, servings/d 0.6 0.6 0.6 0.5 0.4 
aHEI (excluding EPA + DHA) 42 43 45 47 50 
Total energy intake, Kcal/d 1,728 1,761 1,769 1,748 1,700 
HPFS 
     
Participants, No. 6,132 6,148 6,140 6,163 6,112 
Age, y 63 64 64 64 65 
¶
BMI, kg/m
2
 26.2 26.2 26.3 26.1 26.0 
Caucasians, % 97 96 96 95 93 
Current smokers, % 6 6 5 5 4 
Pack years of smoking 13 12 12 11 10 
Physical activity, MET-h/wk 32 33 35 35 39 
Hypertension, % 35 36 37 38 39 
Hypercholesterolemia, % 42 46 49 51 52 
Current aspirin use, % 59 62 62 62 62 
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Table 2.1. (Continued) Age-standardized characteristics of participants according to 
cumulative average intake of EPA + DHA in 1998 (middle of follow-up) 
 EPA + DHA (diet + supplements), Quintiles 
 Q1 Q2 Q3 Q4 Q5 
Fish oil supplements, % 0 1 2 6 16 
Dietary intake 
     
ALA, mg/d 1,113 1,111 1,110 1,102 1,122 
EPA + DHA, mg/d 93 184 268 373 697 
LA, g/d 11 11 11 11 11 
Fruits and vegetables, servings/d 5 5 6 6 7 
Red meat, servings/d 0.7 0.7 0.6 0.5 0.4 
aHEI (excluding EPA + DHA) 43 44 46 48 51 
Total energy intake, Kcal/d 1,982 2,015 2,011 1,951 1,933 
All the values (except for age) are medians or percentages and are standardized to the age distribution of 
the study population 
Abbreviations: MET-h, hours of metabolic equivalent tasks; aHEI, alternative healthy eating index; BMI, 
body mass index; ALA, α-linolenic acid; LA, linoleic acid. 
¶
BMI is calculated as weight in kilograms divided by height in meters squared. 
§
Current menopausal hormone use among postmenopausal women.
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Table 2.2. Hazard ratios of intermediate and advanced AMD according to cumulative average intake of EPA and DHA 
 Quintiles  
 
Q1 Q2 Q3 Q4 Q5 p trend 
Intermediate AMD 
      EPA 
      NHS 
        Median (mg/d) 15 35 54 82 140 
   Cases/person-years 236 /300,256 260 /297,224 229 /303,226 254 /306,019 230 /302,315 
   Age-adjusted HR 1 (ref) 1.10 0.95 1.03 0.90 0.14 
  Multivariate HR (95% CI) 1 (ref) 1.06 (0.89,1.27) 0.92 (0.76,1.10) 1.00 (0.83,1.2) 0.88 (0.73,1.07) 0.13 
HPFS 
        Median (mg/d) 25 58 93 135 248 
   Cases/person-years 80 /122,739 86 /123,084 68 /124,924 67 /121,765 79 /122,436 
   Age-adjusted HR 1 (ref) 1.02 0.81 0.8 0.86 0.21 
  Multivariate HR (95% CI) 1 (ref) 1.01 (0.74,1.37) 0.80 (0.58,1.11) 0.84 (0.6,01.17) 0.90 (0.65,1.25) 0.47 
Pooled 1 (ref) 1.06 (0.91,1.23) 0.90 (0.76,1.05) 0.96 (0.82,1.13) 0.89 (0.75,1.05) 0.09 
DHA 
      NHS 
        Median (mg/d) 52 89 123 169 279 
   Cases/person-years 259 /302,824 238 /297,361 249 /305,730 253 /300,047 210 /303,078 
   Age-adjusted HR 1 (ref) 0.94 0.96 0.97 0.77 0.008 
  Multivariate HR (95% CI) 1 (ref) 0.93 (0.78,1.11) 0.94 (0.79,1.12) 0.95 (0.80,1.14) 0.76 (0.62,0.92) 0.008 
HPFS 
        Median (mg/d) 70 128 180 246 390 
   Cases/person-years 84 /122,484 82 /124,126 68 /122,714 67 /121,959 79 /123,665 
   Age-adjusted HR 1 (ref) 0.93 0.80 0.77 0.81 0.14 
  Multivariate HR (95% CI) 1 (ref) 0.91 (0.67,1.23) 0.80 (0.58,1.11) 0.80 (0.58,1.12) 0.85 (0.61,1.18) 0.35 
Pooled 1 (ref) 0.93 (0.80,1.08) 0.91 (0.78,1.07) 0.92 (0.79,1.07) 0.78 (0.66,0.92) 0.008 
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Table 2.2. (Continued) Hazard ratios of intermediate and advanced AMD according to cumulative average intake of EPA 
and DHA 
 Quintiles 
 Q1 Q2 Q3 Q4 Q5 p trend 
EPA + DHA 
      NHS 
        Median (mg/d) 70 123 179 250 390 
   Cases/person-years 252 /301,969 248 /299,460 228 /302,148 262 /302,831 219 /302,632 
   Age-adjusted HR 1 (ref) 1 0.90 1.02 0.82 0.04 
  Multivariate HR (95% CI) 1 (ref) 0.98 (0.82,1.17) 0.88 (0.74,1.06) 1.00 (0.84,1.19) 0.80 (0.66,0.97) 0.03 
HPFS 
        Median (mg/d) 94 187 275 380 625 
   Cases/person-years 80 /121,668 89 /124,756 71 /122,400 58 /122,937 82 /123,188 
   Age-adjusted HR 1 (ref) 1.05 0.86 0.69 0.87 0.15 
  Multivariate HR (95% CI) 1 (ref) 1.03 (0.76,1.40) 0.86 (0.62,1.19) 0.73 (0.52,1.03) 0.92 (0.66,1.27) 0.38 
Pooled 1 (ref) 1.00 (0.86,1.17) 0.88 (0.75,1.04) 0.94 (0.80,1.10) 0.83 (0.71,0.98) 0.03 
EPA + DHA (supplement users excluded) 
     NHS 
        Median(mg/d) 66 118 170 233 355 
   Cases/person-years 237 /286,521 234 /281,743 213 /281,446 232 /280,475 207 /275,902 
   Age-adjusted HR 1 (ref) 1.01 0.91 0.98 0.86 0.09 
  Multivariate HR (95% CI) 1 (ref) 0.99 (0.82,1.19) 0.89 (0.74,1.08) 0.96 (0.80,1.16) 0.84 (0.69,1.03) 0.09 
HPFS 
        Median(mg/d) 90 180 260 358 564 
   Cases/person-years 76 /114,609 83 /114,692 61 /111,874 55 /111,261 69 /109,760 
   Age-adjusted HR 1 (ref) 1.04 0.81 0.71 0.81 0.07 
  Multivariate HR (95% CI) 1 (ref) 1.03 (0.75,1.41) 0.80 (0.57,1.13) 0.76 (0.53,1.08) 0.88 (0.63,1.25) 0.29 
Pooled 1 (ref) 1.01 (0.86,1.18) 0.88 (0.75,1.04) 0.92 (0.78,1.08) 0.86 (0.72,1.02) 0.04 
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Table 2.2. (Continued) Hazard ratios of intermediate and advanced AMD according to cumulative average intake of EPA 
and DHA 
 Quintiles 
 Q1 Q2 Q3 Q4 Q5 p trend 
Advanced AMD 
      EPA 
      NHS 
        Cases/person-years 182 /300,294 201 /297,277 198 /303,243 225 /306,041 204 /302,325 
   Age-adjusted HR 1 (ref) 1.11 1.07 1.20 1.06 0.60 
  Multivariate HR (95% CI) 1 (ref) 1.07 (0.88,1.31) 1.05 (0.86,1.29) 1.21 (0.99,1.48) 1.11 (0.89,1.36) 0.29 
HPFS 
        Cases/person-years 80 /122,749 66 /123,111 64 /124,929 62 /121,771 74 /122,437 
   Age-adjusted HR 1 (ref) 0.81 0.77 0.77 0.82 0.37 
  Multivariate HR (95% CI) 1 (ref) 0.84 (0.60,1.16) 0.82 (0.59,1.14) 0.88 (0.62,1.23) 0.99 (0.71,1.38) 0.70 
Pooled 1 (ref) 1.00 (0.84,1.19) 0.98 (0.83,1.17) 1.11 (0.94,1.32) 1.07 (0.89,1.28) 0.37 
DHA 
      NHS 
        Cases/person-years 185 /302,871 216 /297,373 205 /305,774 210 /300,073 194 /303,089 
   Age-adjusted HR 1 (ref) 1.21 1.12 1.15 1.02 0.66 
  Multivariate HR (95% CI) 1 (ref) 1.20 (0.98,1.46) 1.12 (0.92,1.37) 1.17 (0.96,1.44) 1.06 (0.86,1.32) 0.90 
HPFS 
        Cases/person-years 84 /122,496 65 /124,148 71 /122,708 54 /121,976 72 /123,669 
   Age-adjusted HR 1 (ref) 0.75 0.82 0.62 0.75 0.10 
  Multivariate HR (95% CI) 1 (ref) 0.76 (0.55,1.05) 0.87 (0.63,1.21) 0.71 (0.50,1.01) 0.89 (0.64,1.24) 0.67 
Pooled 1 (ref) 1.06 (0.90,1.26) 1.04 (0.88,1.24) 1.03 (0.86,1.23) 1.01 (0.84,1.21) 0.75 
EPA + DHA 
      NHS 
        Cases/person-years 177 /302,026 216 /299,479 205 /302,179 211 /302,856 201 /302,639 
   Age-adjusted HR 1 (ref) 1.25 1.17 1.20 1.09 0.93 
  Multivariate HR (95% CI) 1 (ref) 1.23 (1.01,1.50) 1.17 (0.96,1.44) 1.22 (0.99,1.5) 1.15 (0.93,1.42) 0.49 
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Table 2.2. (Continued) Hazard ratios of intermediate and advanced AMD according to cumulative average intake of EPA 
and DHA 
 Quintiles 
 Q1 Q2 Q3 Q4 Q5 p trend 
HPFS 
        Cases/person-years 78 /121,683 74 /124,775 62 /122,405 62 /122,938 70 /123,196 
   Age-adjusted HR 1 (ref) 0.91 0.76 0.77 0.78 0.13 
  Multivariate HR (95% CI) 1 (ref) 0.93 (0.68,1.28) 0.82 (0.58,1.15) 0.88 (0.62,1.24) 0.93 (0.66,1.31) 0.77 
Pooled 1 (ref) 1.14 (0.96,1.35) 1.06 (0.89,1.27) 1.11 (0.93,1.33) 1.08 (0.90,1.29) 0.86 
EPA + DHA (supplement users excluded) 
     NHS 
        Cases/person-years 170 /286,565 189 /281,778 187 /281,460 195 /280,510 178 /275,921 
   Age-adjusted HR 1 (ref) 1.15 1.14 1.17 1.06 0.82 
  Multivariate HR (95% CI) 1 (ref) 1.12 (0.91,1.38) 1.13 (0.91,1.39) 1.18 (0.95,1.45) 1.08 (0.87,1.35) 0.57 
HPFS 
        Cases/person-years 77 /114,618 64 /114,715 63 /111,870 52 /111,272 47 /109,775 
   Age-adjusted HR 1 (ref) 0.81 0.81 0.68 0.56 0.002 
  Multivariate HR (95% CI) 1 (ref) 0.82 (0.59,1.15) 0.85 (0.61,1.20) 0.77 (0.53,1.10) 0.68 (0.46,0.99) 0.05 
Pooled 1 (ref) 1.03 (0.86,1.23) 1.04 (0.87,1.24) 1.05 (0.88,1.26) 0.96 (0.79,1.16) 0.29 
Multivariate models were adjusted for: age (continuous), race (Caucasians or not), BMI (<18.5, 18.5-23, 23-25, 25-30, 30-35, ≥ 35 kg/m2), pack-
years of smoking (never, 1-9, 10-24, 25-44, 45-64, ≥65y), physical activity (<3, 3-8.9, 9-17.9, 18-26.9, ≥27 MET-h/wk), current aspirin use (≥1 
tablets/wk or none), history of hypertension and hypercholesterolemia, dietary variables including aHEI (excluding EPA and DHA), ALA, total 
energy intake (all in quintiles). In NHS, models were additionally adjusted for postmenopausal status and menopausal hormone use (never, current 
and past).  
DHA and EPA included intake from diet and supplements unless otherwise specified.
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Table 2.3. Pooled hazard ratios of intermediate and advanced AMD according to cumulative average intake of fish  
    Servings/wk 
 
Multivariate HR (95% CI) 
 Fish
ǂ
 
 
Median 
 
Almost never 1-3 servings/mo 1 serving/wk 2-4 servings/wk ≥ 5 servings/wk p trend 
Intermediate AMD       
Canned tuna 
 
0.70 
 
1 (ref) 0.94 (0.83,1.07) 0.84 (0.73, 0.96) 0.68 (0.44,1.05) 0.005 
Dark fish 
 
0.20 
 
1 (ref) 1.08 (0.91,1.27) 0.92 (0.74, 1.14) 
 
0.74 
Other fish
a
   0.58  1 (ref) 0.96 (0.85,1.09) 0.91 (0.79, 1.05) 0.91 (0.45,1.83) 0.25 
Total fatty fish
b
 
 
0.98 
 
1 (ref) 0.92 (0.80,1.06) 0.95 (0.82,1.10) 0.79 (0.65,0.96) 0.61 (0.46,0.81) <.001 
Advanced AMD       
Canned tuna  0.70  1 (ref) 1.10 (0.96,1.26) 1.00 (0.86,1.16) 0.76 (0.46,1.23) 0.34 
Dark fish  0.20  1 (ref) 1.04 (0.87,1.24) 0.98 (0.78,1.23)  0.97 
Other fish
a
   0.58  1 (ref) 1.08 (0.94,1.23) 1.04 (0.89,1.22) 1.00 (0.44,2.24) 0.63 
Total fatty fish
b
  0.98  1 (ref) 1.10 (0.94,1.29) 1.05 (0.90,1.24) 0.99 (0.80,1.22) 0.80 (0.59,1.08) 0.11 
ǂ
 Multivariate models were adjusted for the same variable as in Table 2. 
a
Other fish were mainly white fish. 
b
Total fatty fish was the sum of canned tuna and dark fish. Finer intake categories were created to show detailed associations.
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Figure 2.1. Time trend of age-adjusted mean intake of EPA + DHA, fatty fish and fish oil 
supplements  
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Figure 2.2. Pooled hazard ratios of AMD according to dietary intake, predicted erythrocyte and plasma scores of EPA and 
DHA among non-users of fish oil supplements 
 
                                                         Multivariate-adjusted HR
§
 comparing top to bottom quintiles 
§
Multivariate models were adjusted for the same variables as in the Table 2.2 
*p for heterogeneity between the HRs from the NHS and HPFS was < 0.05  
.
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ABSTRACT 
Background: Some observational studies suggested that marine omega3 fatty acids were 
protective for age-related macular degeneration (AMD). However, the role for the plant-derived 
shorter-chain omega3 fatty acid, α-linoleic acid (ALA), is unclear. European researchers reported 
that up to 40% of ALA can be present as trans forms. 
Objectives: To evaluate the associations between intake of ALA and the intermediate and 
advanced AMD. 
Design: 75,889 women from Nurses’ Health Study and 38,961 men from Health Professionals 
Follow-Up Study were followed from 1984 to 2012 and 1986 to 2010, respectively. We assessed 
dietary intake by a validated food frequency questionnaire at baseline and every four years. 
During the follow-up, we confirmed 1,589 incident intermediate and 1,356 advanced AMD cases 
(primarily neovascular AMD) by medical record review. 
Results: Higher intake of ALA was significantly associated with intermediate AMD before 2002 
(comparing extreme quintiles, pooled HR = 1.36; 95% CI = 1.06 – 1.75; p trend = 0.008) but not 
after 2002 (pooled HR = 0.85; 95% CI = 0.64 – 1.13; p trend = 0.21), and p for interaction = 
0.003. ALA intake was not associated with advanced AMD in either time period. By gas-liquid 
chromatography, we identified both cis ALA (mean, 0.13 ± 0.04%) and trans ALA isomers 
(mean, 0.05 ± 0.01%) in 395 erythrocyte samples collected in1989 -1990. In stepwise regression 
models, mayonnaise was the leading predictor of erythrocyte levels of cis ALA and one isomer 
of trans ALA. We also found trans ALA isomers in mayonnaise samples.  
Conclusion: High intake of ALA was associated with an increased risk of intermediate AMD 
before 2002. This coincides with the same time period when trans ALA was found in 
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participants’ blood and in mayonnaise, a primary food source of ALA. Whether trans ALA 
mediates this positive association warrants further studies. 
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I. Introduction  
Age-related macular degeneration (AMD) is a chronic, progressive disease that can cause 
irreversible blindness.
1
 According to the 2005-2008 US National Health and Nutrition 
Examination Survey (NHANES), the estimated prevalence in persons aged 40 years and older 
was 5.7% for early/intermediate AMD versus 0.8% for advanced AMD.
2
  Because the number of 
AMD patients is expected to grow exponentially in the next few decades in the US and 
worldwide as populations ages,
3-5
 the identification of potential strategies for primary prevention 
would have marked public health significance. 
Marine long-chain omega3 (n3) fatty acids, including eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA), have been associated with a lower risk of AMD in multiple 
observational studies.
6-10
 However, epidemiologic research on the shorter-chain n3 fatty acid, α-
linolenic acid (ALA), has yielded inconsistent findings. Some studies reported a positive 
association for intake of ALA
6,11
 and vegetable fat foods
12-14
 that contain ALA whereas others 
did not.
7,8,15,16
 Additional studies of ALA’s effects are needed because this plant-derived fatty 
acid accounts for at least 85% of total n3 fatty acid intake in the US
17
 and, presumably even 
more, in parts of the world where access to fish is limited. 
Trans ALA is formed during partial hydrogenation, deep frying and industrial deodorization
18,19
 
and is hypothesized to interfere with the crucial biological functions of cis ALA. Trans ALA has 
not received much attention in the US. However, European researchers have reported the 
presence of trans isomers of ALA in food such as vegetable oils,
18,20
 low-calorie spreads
21
 and 
infant formulas
22,23
. Up to 40% of ALA can be present as trans isomers.
19,20
 Trans ALA also 
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occurs in human serum
24
 and maternal milk
25,26
. Rats fed a diet high in trans ALA developed 
disturbed visual function and a decrease in cis DHA in the retina.
27,28
  
We previously reported a positive association between intake of ALA and AMD.
6
 With 16 years 
longer follow-up and 2,500 more AMD cases than our previous study, we aimed to evaluate this 
association in greater detail. Our secondary aim was to explore the role of trans ALA in the 
development of AMD. 
II. Methods 
Study Population 
The Nurses’ Health Study (NHS), initiated in 1976, is an ongoing prospective cohort that 
includes 121,700 US female registered nurses aged between 30 to 55 years at baseline. The 
Health Professionals Follow-up Study (HPFS), initiated in 1986, includes 51,529 US male health 
professionals aged between 40 and 75 years at baseline. Both cohorts are predominantly white. 
Participants are mailed biennial questionnaires about lifestyle factors and disease outcomes, and 
food frequency questionnaires (FFQ’s) every four years to assess diet in the preceding years. The 
follow-up rates for both cohorts are high (>95%). The study protocol was approved by the 
Institutional Review Boards at the Brigham and Women's Hospital and Harvard T.H. Chan 
School of Public Health. 
We restricted the study population to those who were ≥50 years old at baseline and then added 
participants to the analysis once they reached age 50 years. Participants were censored at age 90 
years to alleviate the concern of lower ascertainment of AMD cases (NHS, n=15; HPFS, n=528). 
At baseline, we excluded participants who did not return the initial FFQ, left more than 70 food 
items blank in the FFQ, reported implausible dietary intake (<600 or >3500 Kcal/d for the NHS 
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and <800 or > 4200 Kcal/d for the HPFS), had prevalent AMD, cancer (except nonmelanoma 
skin cancer), diabetes and cardiovascular disease. To minimize detection bias, we also excluded 
participants who never reported an eye exam over the entire follow-up period and skipped the 
person-time during any two-year interval in which they did not report an eye exam. Results did 
not materially change in sensitivity analyses including intervals lacking an eye exam.  After 
exclusions, a total of 75,889 women and 38,961 men contributed to the analysis.  
AMD Ascertainment 
Our case definition has been previously validated by comparison with retinal images  and 
medical records.
29
 When a participant reported a diagnosis of AMD on a biennial questionnaire, 
we requested informed consent to review his/her medical record and then contacted the 
participant’s eye doctor to either complete a standardized questionnaire or to send us copies of 
ocular records to confirm the diagnosis. The questionnaire requested information from the 
medical record on the date of initial diagnosis, treatment received for AMD, clinical signs of 
AMD, best corrected visual acuity, and whether, in the opinion of the treating doctor, the visual 
acuity loss was due primarily to AMD. Photos and/or OCTs were also reviewed when available 
to confirm clinical AMD lesions. We excluded cases with only small hard drusen (drusen size< 
63 μm diameter circle). We defined intermediate AMD as having at least one of the following 
signs in at least one eye: intermediate drusen ( ≥ 63 and <125 µm), pigment abnormalities, large 
drusen (≥ 125 µm) or any non-central geographic atrophy (GA). We defined neovascular AMD 
as having any of the following signs in at least one eye: RPE detachment, subretinal neovascular 
membrane, disciform scar, or history of treatment with laser, photodynamic, or anti-VEGF 
therapy for AMD. Central GA was defined as having a central geographic atrophy lesion 
involving the center of the macula in at least one eye. Advanced AMD included both neovascular 
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AMD and central GA. Additionally, all case definitions, except those recent neovascular AMD 
cases that had anti-VEGF therapies, included a visual acuity of 20/30 or worse due primarily to 
AMD. This magnitude of vision loss is not only of clinical significance, but also is severe 
enough to warrant medical attention so as to minimize potential detection bias arising from 
differential health consciousness. The person was used as the unit of analysis, and the worst eye 
was used for classification.  
Dietary Assessment 
We began follow up in 1986 for the HPFS and 1984 for the NHS, when the first comprehensive 
FFQ with 131 items was administered, and assessed dietary intake approximately every four 
years thereafter. Intake of ALA is from many foods but the major sources among FFQ items 
include 1) mayonnaise or other creamy salad dressing (1 tbs); 2) oil and vinegar dressing (e.g. 
Italian,1 tbs); 3) beef, pork or lamb as a main dish (4-6 oz); 4) margarine (1 pat); 5) other cheese 
(e.g. American, cheddar, 1 slice or 1 oz serving). These foods collectively accounted for 46% of 
ALA intake in the NHS and 38% in the HPFS at baseline. However, the total contribution from 
these foods decreased to 16% in 2010 in the NHS and 12% in 2006 in the HPFS. Walnut 
consumption (1 oz) was asked from the 1998 FFQ and onward, which became the top contributor 
to ALA intake (18% in the NHS and 17% in the HPFS). Low-fat mayonnaise consumption (1 tbs) 
was asked from the 1994 FFQ and onward. We started asking the intake of flax seed oil and flax 
seed (Yes or No) from the 2006 FFQ in the NHS and further inquired the frequency of intake for 
flax seed (1 Tbs) in the 2010 FFQ in both the NHS and HPFS. Participants were asked to report 
how often, on average over the past year, they had consumed each food item (9 possible 
responses ranging from “≤1 time per month” to “≥6 times/day”). The FFQs specifically inquired 
about the usual type of fat used for frying, sautéing and baking. It also inquired about the usual 
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brand and type of margarine using an open-ended question. Such information was taken into 
account when calculating ALA intake. The daily nutrient intake was calculated by multiplying 
the consumption frequency of each food by its nutrient content and then summing across all 
foods. The fatty acid composition of food fried, baked or sautéed at home was modified by the 
type of fat reported. The nutrient composition data were primarily based on the US Department 
of Agriculture Nutrient Database supplemented with information from manufacturers and 
published reports. We adjusted all the nutrient intakes for total energy using the residual method 
to reflect the composition of the diet.
30
  
The reproducibility and validity of FFQs in measuring fat intake has been assessed in both 
cohorts. The Pearson correlations between energy-adjusted intake of different fatty acids from 
two 1-wk diet records and from the FFQ ranged from 0.48 to 0.73 in the NHS
31
 and from 0.37 to 
0.75 in the HPFS
32
. The Spearman correlation between the percentage of fat intake calculated 
from the FFQ and the proportion of that fat in the adipose tissue was 0.34 for ALA, 0.37 for 
linoleic acid, and 0.40 for trans fatty acids in the NHS
33
 and 0.50 for polyunsaturated fatty acids, 
0.47 for linoleic acid (LA) and 0.29 for trans fatty acids in the HPFS
34
.  
Measurement of trans ALA and cis ALA  
To confirm the presence of trans ALA in food supplies and in human bodies, we measured trans 
ALA among erythrocyte samples (n=395) from the NHS participants by gas-liquid 
chromatography and also re-analyzed some existing chromatography of mayonnaise samples 
collected before and after 2000. The methods were described elsewhere.
35
 Each trans ALA peak 
was identified by comparison with trans ALA standards (linolenic acid methyl ester isomer mix, 
purchased from Sigma-Aldrich) and the amount was expressed as the percentage of total peak 
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area. We identified four trans ALA isomers: trans ALA-A and -B have two trans double bonds 
while trans ALA-C and -D have one trans double bond. The concentration of erythrocyte trans 
ALA-A was extremely low and below the meaningful concentration (mean < 0.01%) and was 
thus not included in the analysis. The overall coefficients of variations (CV) for trans ALA-B, -C, 
and -D were 23.6%, 33.4% and 40.8%, respectively. Higher CVs for trans ALA-C and -D were 
likely due to the overlapping of those two peaks with 11t-Eicosenoic Acid (20:1n-9t) and 8c-
Eicosenoic Acid (20:1n-12c), respectively. However, because the within-batch CV for each peak 
was <20% (an acceptable limit), we statistically accounted for the high overall CVs by 
recalibrating the concentration of each trans ALA isomer from all batches to its average batch 
according to a method outlined by Rosner et al.
36
 Because trans ALA-C and -D peaks usually 
overlapped in chromatography, we combined those two in the analysis to reduce measurement 
error. We estimated the reproducibility of erythrocyte trans ALA by re-analyzing existing 
chromatography from an earlier within-person stability study where 40 postmenopausal women 
gave three blood samples over 2-3 years.
37
 In that study, the intra-class correlation (ICC) for cis 
ALA was 0.52. The ICC we calculated was 0.53 for trans ALA-B, 0.56 for trans ALA-C and 
0.43 for trans ALA-D, all indicating fair to good reproducibility.  
To better understand the food determinants of physiologic cis ALA level, we used previously 
measured blood biomarker data among participants of nested case-control studies of 
cardiovascular disease in the NHS and HPFS. We included all the cases and controls because 
cases were not yet cases at the time of blood collection. The details on blood collection and 
measurements have been previously described.
38,39
  
Statistical Analysis 
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Participants contributed person-time to the analysis from the return of the baseline questionnaire 
if over age 50 years at baseline or from reaching 50 years old to the confirmed diagnosis of 
AMD, death, loss to follow-up or the end of follow-up (05/31/2012 for the NHS and 01/31/2010 
for the HPFS), whichever occurred first. To best represent long-term intake and minimize 
measurement error,
40
 we calculated the cumulative average intake of ALA by averaging all 
available FFQs up to the start of each two-year risk interval. The cumulative average value was 
categorized into quintiles based on the distribution in each cohort. Likewise, we calculated the 
cumulative average intakes of foods and categorize them into pre-specified groups. 
We used time-varying Cox proportional hazards models to estimate the hazard ratios (HR) and 
95% confidence intervals (CI) associated with intermediate and advanced AMD, respectively. To 
control as finely as possible for confounding by age and calendar time and any possible two-way 
interactions between these two time scales, we stratified the model jointly by age in months at 
the start of follow-up and calendar year of the current questionnaire cycle. We controlled for 
established and probable risk factors including race, body mass index (BMI), pack-years of 
smoking, physical activity, aspirin use, history of hypertension, history of hypercholesterolemia, 
menopausal status and postmenopausal hormone use (in the NHS only), dietary variables 
including intakes of total energy intake, LA and DHA.  
One way of generating trans ALA is by industrial partial hydrogenation.
21
 From early 2000s 
there was an increasing public awareness of adverse health effects by trans fatty acids and food 
industries started to reduce or eliminate them.
41,42
 Several studies found a downward trend of 
total trans intake
43
 and plasma level
44
 around that time. We thus chose 2002 as the cutoff to 
evaluate the differential association between intake of ALA and AMD in the pre-2002 and post-
2002 eras due to a potential change in trans ALA content over time. We calculated the 
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cumulative average of ALA intake separately in each time period. We created interaction terms 
between the time-varying ALA variable and the binary indicator for time period and used a 
likelihood ratio test to test the significance of interaction by time comparing models with and 
without the interaction terms. A similar approach was used to test interactions between intake of 
ALA and pre-specified risk factors including age, smoking status and menopausal hormone use. 
To better understand the food determinants of cis and trans ALA on a physiologic level, we used 
stepwise linear regressions to select foods that were significantly predictive of the biomarker 
measurements (p < 0.05). This method has been described previously.
45,46
 Briefly, we used the 
average of food intake from the 1986 and 1990 FFQs in the NHS and from the 1990 and 1994 
FFQs in the HPFS to reduce the within-person variation of intake and to correspond with the 
time of blood draw. We developed the linear regression model by the biomarker type in each 
cohort.  
We performed the statistical analyses separately in each cohort using SAS 9.3 (SAS Institute, 
Cary, NC). To derive a pooled HR, we first combined the two cohorts and then applied a Cox 
proportional hazards model in the pooled data stratified by the cohort. Interpretation of the data 
was mainly based on pooled HRs unless otherwise specified. All hypothesis tests were two-sided 
and used an α level of 0.05. 
III. Results 
Study During 28 years of follow-up in the NHS and 24 years in the HPFS, we confirmed 2,219 
incident AMD cases (1,209 intermediate + 1,010 advanced cases) in women and 726 (380 
intermediate + 346 advanced cases) cases in men. The advanced AMD cases were predominantly 
neovascular AMD (>96%).  
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In 1998 (the middle of follow-up), participants at the highest cumulative average intake of ALA 
were likely to have a higher BMI and pack-years of smoking and were less likely to exercise and 
have hypercholesterolemia (Table 3.1). In terms of dietary intake, they were likely to have higher 
intakes of DHA, LA, trans fat and saturated fat, but overall a higher healthy eating score.   
ALA intake was moderately correlated (average pearson r = 0.62) with LA intake, the omega6 
analog fatty acid that shares many food sources with ALA, but weakly correlated with intake of 
food-sourced EPA (r = 0.10) or DHA (r = 0.06). During the follow-up, the age-adjusted intake of 
ALA has increased about 50% in the NHS from 1984 (median intake, 1.03 g/d) to 2010 (1.58 
g/d), and 29% in the HPFS from 1986 (1.12 g/d) to 2006 (1.44 g/d). In contrast, the intake of 
food-sourced EPA + DHA did not appreciably change during the follow-up (data not shown).   
In the pooled analysis between the NHS and HPFS, comparing extreme quintiles, intake of ALA 
had a statistically significant positive association with intermediate AMD (comparing extreme 
quintiles, HR = 1.31; 95% CI = 1.21 – 1.53; p trend <.001) and this association was essentially 
unaltered after further adjusting for LA or saturated, monounsaturated and trans fatty acids 
(Table 3.2). The multivariate-adjusted HR for ALA was in the positive direction in each cohort 
although was only statistically significant in the NHS. For the baseline 1986 FFQ in the HPFS, 
we have further separated intake of ALA by animal and plant sources (such information was not 
available in the NHS). The median baseline intake was 350mg g/d for animal-sourced ALA and 
700 mg/d for plant-sourced ALA, and they were weakly negatively correlated (Pearson r = - 
0.22). Comparing extreme quintiles, plant-sourced ALA (adjusted HR = 1.54; 95% CI = 1.04 – 
2.28; p trend = 0.03) was more strongly associated with intermediate AMD than the animal-
sourced counterpart (adjusted HR = 1.17; 95% CI = 0.85 – 1.62; p trend = 0.22). When they were 
mutually adjusted for each other, the HR did not materially change for plant-sourced ALA 
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(adjusted HR = 1.60; 95% CI = 1.08 – 2.38; p trend = 0.02) nor for animal-sourced ALA 
(adjusted HR = 1.23; 95% CI = 0.89 – 1.70; p trend = 0.13). Comparing extreme quintiles, intake 
of LA also had a positive association with intermediate AMD (adjusted HR = 1.22; 95% CI = 
1.05 – 1.42; p trend = 0.006); however, after further adjusting for ALA, the association was 
attenuated and no longer significant (adjusted HR = 1.06; 95% CI = 0.88 – 1.27; p trend = 0.50).  
In contrast, we did not find any significant association between intake of ALA and advanced 
AMD after multivariate adjustment (Table 3.2), nor for LA (pooled HR for comparing extreme 
quintiles = 1.08; 95% CI = 0.91 – 1.28; p trend = 0.25). 
The association between intake of ALA and intermediate AMD was only apparent among never 
smokers (pooled HR comparing extreme quintiles = 1.66; 95% CI = 1.23-2.22; p trend = 0.001) 
as compared with ever smokers (pooled HR comparing extreme quintiles = 1.07; 95% CI = 0.83-
1.37; p trend = 0.001) (p for interaction = 0.10) (Supplementary Table 3.1). There was no 
significant interaction by age (Supplementary Table 3.2). 
To understand whether the association with intermediate AMD was specific to ALA, we 
examined the intakes of several other correlated fatty acids including cis 18:1, trans 18:1, cis 
18:2, trans 18:2, saturated fat, and total trans fatty acids. Comparing extreme quintiles, intakes 
of cis 18:1, cis 18:2, trans 18:2, and saturated fat each had a significant positive association with 
intermediate AMD (Supplementary Figure 3.1). However, all the associations were attenuated 
and no longer statistically significant after adjusting for ALA, whereas in all scenarios ALA 
persisted with a significant positive association (Supplementary Figure 3.1). On the other hand, 
intakes of trans 18:1 (p trend = 0.05), trans 18:2 (p trend = 0.04) and total trans fatty acids (p 
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trend = 0.03) had a suggestively significant association with advanced AMD after adjusting for 
ALA (Supplementary Figure 3.2).  
We identified several trans ALA isomers in erythrocytes and mayonnaise (Figure 3.1). The 
amount of total trans ALA (mean, 0.05 ± 0.01%) was lower compared to cis ALA (mean, 0.13 ± 
0.04 %) in erythrocytes (Supplementary Table 3.3). Among individual isomers of trans ALA, the 
correlation with cis ALA was much stronger for trans ALA-B (Pearson r=0.65) as compared 
with trans C / D (r=0.17) (Supplementary Table 3.4). Mayonnaise was the leading significant 
predictor for both cis ALA and trans ALA-B (Supplementary Table 3.3). Mayonnaise was also 
positively related to the plasma and erythrocyte level of cis ALA among previously measured 
samples (Supplementary Table 3.5). Intake of mayonnaise before 2002 was associated with the 
risk of intermediate AMD (HR for per 5 servings/week increase = 1.30; 95% CI = 1.07-1.57; p 
trend = 0.009) (Figure 3.2). 
Although we were unable to quantify the intake of trans ALA because our nutrient database does 
not currently contain such information, we designed several exploratory analyses to evaluate 
whether trans ALA might be responsible for the positive association between ALA and 
intermediate AMD using the intake of total ALA, especially during the early follow-up period, as 
a proxy for trans ALA.  
1. Stratified analysis by time period before and after 2002 
We speculated that the intake of trans ALA would be higher prior to 2002 when trans fatty acids 
were more prevalent. Our own data also lend some support to this speculation. Comparing the 
representative mayonnaise sample collected before 2000 to the one after 2000, the percentage of 
trans ALA among total ALA (cis + trans) decreased from 11.8% to 5.0%. Comparatively, the 
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percentage of trans 18:2 among total 18:2 (cis + trans) decreased from 0.88% to 0.69%. 
Therefore, we hypothesize that the positive association between intake of ALA and intermediate 
AMD would be stronger prior to 2002 than after. Consistent with our hypothesis, comparing 
extreme quintiles, intake of ALA was positively associated with intermediate AMD before 2002 
but not after 2002 and the interaction by time period was significant (p=0.003) (Table 3.3). There 
was no significant association between intake of ALA and advanced AMD in either time period. 
Mayonnaise and oil & vinegar salad dressing were both positively associated with intermediate 
AMD before 2002 but neither were after 2002, nor did any other major ALA-bearing foods 
(Figure 3.2). In a sensitivity analysis, we used 1998 instead of 2002 as the cutoff for the two time 
periods. The association between intake of ALA and intermediate AMD in each time period did 
not materially change; the HR comparing extreme quintiles was 1.36 (95% CI = 1.00 – 1.83; p 
trend = 0.02) before 1998 and 1.00 (95% CI = 0.78 – 1.26; p trend = 0.91) after 1998, but the p 
for interaction was slightly attenuated (p = 0.08). 
2. Joint effect with intake of DHA and ALA 
Informed by animal studies, this analysis was based on the hypothesis that trans ALA would 
adversely affect the development of AMD by conversion to trans DHA, which would interfere 
and compete with natural cis DHA for its crucial functions at the retina. Compared to the intake 
level at the top tertile of DHA but bottom tertile of ALA, intake at the bottom tertile of DHA and 
top tertile of ALA had a 46% (HR= 1.46; 95% CI=1.17 - 1.83) increased risk of intermediate 
AMD, but the interaction between ALA and DHA was not statistically significant (p=0.16). 
There was no apparent interaction between ALA and LA (p for interaction = 0.69). 
3. Effect modification by menopausal hormone use 
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Although the conversion rate from ALA to DHA is generally considered low ( ~ 1%), some 
studies observed a 62% higher conversion rate in women taking an oral contraceptives and an 
increased activity of the desaturation/chain elongation pathway in postmenopausal women 
receiving hormone therapy.
47,48
 Based on that, we hypothesized that in postmenopausal women, 
the association between intake of ALA and intermediate AMD would be stronger among current 
users of menopausal hormones than non-current users because more trans ALA could be 
converted to trans DHA. Consistent with our hypothesis, the HR for the association between 
intake of ALA and intermediate AMD among current users was 1.84 (95% CI=1.16 – 2.92; p 
trend=0.04; cases = 315) whereas the HR among non-current users was 1.17 (95% CI=0.89 – 
1.54; p trend=0.17; cases = 789) and the p for interaction = 0.01. When we further restricted this 
analysis to the pre-2002 era, the HR’s among current users was 2.20 (95% CI=1.27 – 3.82; p 
trend=0.03; cases = 235) and among non-current users was 1.12 (95% CI=0.76 – 1.63; p 
trend=0.35; cases = 380) with the p for interaction = 0.005. 
IV. Discussion 
In this large prospective study with 24-28 years of follow-up, high intake of ALA was associated 
with a modest increased risk of visually significant intermediate AMD but not with advanced 
AMD. However, only ALA intake in the pre-2002 era seemed harmful, possibly due to temporal 
changes in the composition of cis and trans isomers in dietary ALA sources. In accordance with 
European studies, our US-based study also identified the presence of trans ALA in human blood 
samples and in food (e.g. mayonnaise). Exploratory analyses suggest a role for trans ALA in the 
development of intermediate AMD.  
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Confounding is the greatest concern for the finding of a positive association between intake of 
ALA and intermediate AMD, because ALA intake in our cohorts was mainly derived from 
vegetable fat foods (e.g. mayonnaise, salad dressing, margarine), processed baked foods and red 
meat.
49
 However, several analyses suggest that ALA is the primary causal factor. First, after 
further adjusting for other fatty acids primarily derived from unhealthy sources, including 
monounsaturated fat (mainly from red meat in our cohorts), saturated fat, and trans fatty acids, 
the result was essentially unchanged. We further found the specificity for the positive association 
with ALA among many correlated fatty acids. Finally, although red meat was associated with 
higher risk of AMD. 
6,50
 the finding that ALA from animal sources had a weaker association with 
intermediate AMD than ALA from vegetable sources reduces the likelihood of major 
confounding.  
The association between intake of ALA and intermediate AMD seemed only apparent among 
never smokers. Smoking is known to increase the oxidative state of the body
51
 and one may 
speculate that this oxidative environment would destroy ALA which is susceptible to oxidation 
due to its highly unsaturated nature. In our blood samples, pack-years of smoking was inversely 
related to plasma or erythrocyte level of ALA in both men and women (data not shown). Several 
other studies also suggested inverse association between smoking status and the blood level of 
long-chain n3 fatty acids.
52-54
 However, an alternative explanation is that, since smoking is a 
strong risk factor for AMD,
29,55
 the impact of ALA may be obscured for smoking-related AMD.   
In accordance with European literature, we were able to confirm trans ALA in food and blood 
samples of US participants, and we also found that one isomer of trans ALA shared the same 
food, mayonnaise, with the cis ALA. Information on the trans ALA intake in the US is virtually 
non-existent likely because the intake of its precursor cis ALA is already much lower compared 
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to oleic acid and LA, the precursors to major trans fatty acids in the US diet. For example, 
according to NHANES 2009-2010 data, the mean intake is 1.50 g/d for ALA, 26 g/d for oleic 
acid and 15 g/d for LA.
56
 However, studies suggested that ALA is 12-15 times more easily to be 
isomerized into trans forms than LA due to its more unsaturated nature and up to 40% of ALA 
can be present as trans isomers in some foods.
19,20
 Based on a few US food samples, we crudely 
estimated the ratio of trans ALA to cis ALA was 1:7.5. Assuming that this ratio is generalizable 
to other trans ALA-containing foods, this translates into an intake of 0.2 g/d of trans ALA on the 
basis of a 1.5 g/d mean intake of ALA in the US population,
17
 which is slightly lower but on the 
same magnitude as the estimated intake among Dutch and Scottish (0.5 - 0.7 g/d) and French 
participants (0.2 - 0.4 g/d).
24
 Our study and the European study
24
 both suggested a low level of 
erythrocyte trans ALA (~ 0.05% of total fatty acids) under a habitual diet. However, a study 
among 50 Indian participants with a high use (86%) of ALA-rich cooking oils - canola and 
mustard, and a high consumption of fried snacks and sweets (>3 days/wk) reported a markedly 
higher level of trans ALA in serum, adipose and cheek epithelium tissues (content ranging from 
1.2-1.8%).
57
 In European study in which 88 healthy men were randomized to receive a diet high 
(1.41 g/d) and low (0.06 g/d) in trans ALA for 6 weeks, the amount of trans ALA on plasma 
lipids was significantly increased compared to the control group.
24
 This study further showed a 
statistically significant increase in LDL:HDL ratio in the high trans ALA group.
58
 These findings 
suggest that body composition of trans ALA level is responsive to dietary intake. 
Our hypothesis that trans ALA accounts for the association with intermediate AMD has some 
biological plausibility. Long-term feeding rats of a diet high in trans ALA severely disturbed 
visual function and also resulted in a significant increase in trans DHA and a decrease in cis 
DHA.
27,28
 In humans, trans ALA is absorbed and incorporated into tissue lipids.
24
 Small amounts 
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of trans EPA and DHA are present in human platelets.
59
 These data suggest that trans ALA may 
affect the development of AMD through conversion to trans DHA, which may interfere with the 
function of natural cis DHA in the retina.  
Data from our exploratory analyses are in line with the hypothesis that trans ALA is implicated 
in the development of intermediate AMD, assuming intake of total ALA is a proxy for trans 
ALA. First, ALA was only associated with higher risk of intermediate AMD during early follow-
up, which can be explained by a higher content of trans ALA in the era of widespread industrial 
partial hydrogenation and less attention to the deodorization of vegetable oils. Second, we found 
a stronger positive association in postmenopausal women currently using exogenous hormones 
than those not. This may be explained by a higher biological conversion rate from trans ALA to 
trans DHA promoted by exogenous hormones. Although the endogenous conversion from ALA 
to DHA is limited in humans (0-4%),
60,61
, the conversion rate was noted to be higher in women 
than men;
47,62
 and it was 62% even greater in those using exogenous hormones.
47,48
 Finally, 
stronger association was found in those with highest intake of ALA and lowest DHA compared 
to the vice versa. An explanation along the same line of biological conversion is that more trans 
DHA would be produced from a high intake of trans ALA which would have a greater adverse 
effect particularly when the intake level of cis DHA was low. However, an alternative 
explanation is that cis ALA would compete with cis DHA in incorporation into membranes. The 
second explanation does not seem to be supported by our data. When we accounted for dietary 
intake of DHA, an increasing plasma or erythrocyte level of ALA was significantly associated 
with a higher (as opposed to a lower) level of plasma or erythrocyte DHA in women (there was 
no statistically significant relation in men), which is more consistent with the hypothesis of 
conversion than competition, and higher conversion rate in women.  
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Only two
6,11
 of previous studies
6-8,11-16
 found a positive association between intake of ALA and 
AMD. Some other studies reported a positive association for vegetable fat foods and processed 
baked goods which contained ALA.
11-13
 Unlike long-chain n3 fatty acids whose dietary intake 
mainly comes from fatty fish or fish oil supplements, ALA is obtained from many different foods. 
Measurement error arising from a single assessment of diet in all previous studies (except ours) 
may have obscured a modest association for ALA.  However, studies that found a positive 
association generally had a larger number of cases and assessed baseline diet in the early 1990s, 
the era when intake of trans ALA was presumably higher. Interestingly, intake of ALA as well 
as mayonnaise before 1995 was also prospectively associated with early age-related lens 
opacities among 440 NHS participants.
63,64
 It would be interesting to see whether ALA, possibly 
the trans isomers, is implicated in a common biological mechanism that underlies the 
pathogenesis of chronic eye diseases.  
Several limitations of our study are worth noting. First, residual confounding cannot be ruled out 
due to the observational nature of our study. Second, measurement error of ALA intake by FFQs 
may lead to an underestimate of the true association. Finally, because some fatty acids overlap 
with trans ALA peaks in chromatography, more rigorous examination is desirable to confirm and 
quantify trans ALA in human tissues and food supply.  
In summary, high intake of the shorter chain n3 fatty acid, ALA, is associated with a 36% higher 
risk of intermediate AMD before 2002. Although intake of ALA seems to be safer after 2002 in 
the US where industrial partial hydrogenation has been greatly reduced, further examination of 
trans ALA in current food supply may still be prudent, in light of FDA’s efforts to eliminate 
industrially produced trans fatty acids from food supply. Partially isomerized sources of ALA 
may still contribute to risk of AMD in some countries where partially hydrogenated oils are 
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widely used or the quality of industrial deodorization of vegetable oils is suboptimal. Studies that 
could directly measure trans ALA are warranted to provide more definitive insights into the role 
of trans ALA in the development of AMD. 
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VI. Tables and Figures 
Table 3.1. Age-standardized characteristics of participants in the NHS and HPFS 
according to cumulative average intake of ALA in 1998 (the middle of follow-up) 
 
ALA, quintiles 
  Q1 Q2 Q3 Q4 Q5 
NHS 
     
Participants, No. 13,257 13,246 13,264 13,258 13,245 
Age, y, median 64 63 63 64 64 
¶
BMI, kg/m
2
, median 26.1 26.6 26.8 27.0 27.1 
Caucasians, % 96 98 98 98 96 
Current smokers, % 10 9 10 10 12 
Pack years of smoking, median 23 23 24 24 26 
Physical activity, MET-h/wk, median 18 18 17 17 16 
Hypertension, % 44 44 44 44 44 
Hypercholesterolemia, % 59 58 57 56 54 
Postmenopausal, % 94 94 94 94 94 
§
Current menopausal hormone use, % 44 45 46 45 45 
Current aspirin use, % 47 49 49 49 47 
Dietary intake, median 
     
               ALA, mg/d 738 860 943 1,036 1,242 
DHA, mg/d 133 137 140 139 143 
LA, g/d 7.3 8.1 8.7 9.3 10.8 
Trans fat, g/d 2.5 2.7 2.9 2.9 3.0 
Saturated fat, g/d 17.7 19.0 19.7 20.4 21.3 
Monounsaturated fat, g/d 19.2 20.8 21.7 22.5 23.7 
Alternative healthy eating index 50.6 50.8 51.0 51.2 52.1 
Total energy intake, kcal/d 1,695 1,743 1,770 1,770 1,732 
HPFS 
     
Participants, No. 6,148 6,115 6,161 6,091 6,180 
Age, y, median 64 64 64 64 64 
¶
BMI, kg/m
2
, median 25.5 26.0 26.3 26.4 26.4 
Caucasians, % 94 95 96 96 95 
Current smokers, % 5 5 4 5 6 
Pack years of smoking, median 11 11 11 12 13 
Physical activity, MET-h/wk, median 35 35 35 35 34 
Hypertension, % 38 38 37 36 37 
Hypercholesterolemia, % 51 50 48 47 45 
Current aspirin use, % 61 63 63 62 58 
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Table 3.1. (Continued) Age-standardized characteristics of participants in the NHS and 
HPFS according to cumulative average intake of ALA in 1998 (the middle of follow-up) 
 ALA, quintiles 
 Q1 Q2 Q3 Q4 Q5 
Dietary intake, median 
     
               ALA, mg/d 840 987 1,085 1,196 1,445 
               DHA, mg/d 206 206 203 206 213 
LA, g/d 9.3 10.2 10.8 11.6 13.2 
Trans fat, g/d 2.8 3.1 3.3 3.4 3.4 
Saturated fat, g/d 19.7 21.7 22.9 23.8 24.9 
Monounsaturated fat, g/d 23.3 25.6 26.9 28.1 29.5 
Alternative healthy eating index 54.0 53.9 53.6 53.8 55.3 
Total energy intake, kcal/d 1,934 1,985 1,997 2,009 1,968 
Abbreviations: MET-h, hours of metabolic equivalent tasks; BMI, body mass index; ALA, α-linolenic 
acid; DHA, Docosahexaenoic acid; LA, linoleic acid. 
 
¶
BMI is calculated as weight in kilograms divided by height in meters squared. 
§
Current menopausal hormone use among postmenopausal women.                                                       
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Table 3.2. Hazard ratios of AMD according to quintiles of cumulative average intake of 
ALA  
 
Q1 Q2 Q3 Q4 Q5 
P for 
trend 
Intermediate AMD       
NHS       
Median (mg/d) 760 805 893 978 1,090 
 
Cases/person-years 211 / 300,584 237 / 301,701 203 / 302,772 273 / 301,809 285 / 302,175 
 
Age-adjusted  model 1 (ref) 
1.19 
(0.99,1.43) 
1.02 
(0.84,1.24) 
1.36 
(1.14,1.63) 
1.38 
(1.15,1.64) 
<.001 
Multivariate model 1 (ref) 
1.17 
(0.97,1.41) 
1.01 
(0.83,1.22) 
1.33 
(1.11,1.60) 
1.34 
(1.12,1.61) 
<.001 
Multivariate model A 1 (ref) 
1.21 
(1.00,1.47) 
1.05 
(0.85,1.29) 
1.38 
(1.12,1.69) 
1.31 
(1.05,1.64) 
0.02 
HPFS       
Median (mg/d) 850 990 1,093 1,213 1,425 
 
Cases/person-years 74 / 122,869 76 / 123,263 67 / 122,309 75 / 123,512 88 / 122,996 
 
Age-adjusted model 1 (ref) 
1.06 
(0.77,1.47) 
0.95 
(0.68,1.32) 
1.06 
(0.77,1.47) 
1.22 
(0.90,1.67) 
0.20 
Multivariate model 1 (ref) 
1.04 
(0.76,1.44) 
0.93 
(0.67,1.30) 
1.03 
(0.75,1.43) 
1.20 
(0.88,1.64) 
0.24 
Multivariate model A 1 (ref) 
1.03 
(0.75,1.43) 
0.92 
(0.65,1.30) 
1.01 
(0.72,1.43) 
1.18 
(0.82,1.69) 
0.37 
Pooled (NHS+HPFS)       
Multivariate model 1 (ref) 
1.15 
(0.97,1.34) 
0.99 
(0.84,1.17) 
1.26 
(1.07,1.47) 
1.31 
(1.12,1.53) 
<.0001 
Multivariate model A 1 (ref) 
1.16 
(0.99,1.37) 
1.01 
(0.85,1.21) 
1.28 
(1.07,1.52) 
1.27 
(1.05,1.54) 
0.01 
Multivariate model B 1 (ref) 
1.17 
(0.99,1.38) 
1.02 
(0.85,1.22) 
1.28 
(1.07,1.54) 
1.28 
(1.05,1.56) 
0.01 
       
Advanced AMD 
     
 
NHS 
     
 
Median (mg/d) 760 805 893 978 1,090 
 
Cases/person-years 189 / 300,571 196 / 301,736 212 / 302,750 195 / 301,877 218 / 302,246 
 
Age-adjusted model 1 (ref) 
1.10 
(0.90,1.35) 
1.20 
(0.99,1.46) 
1.09 
(0.89,1.33) 
1.19 
(0.98,1.44) 
0.14 
Multivariate model 1 (ref) 
1.07 
(0.88,1.31) 
1.15 
(0.94,1.40) 
1.04 
(0.85,1.27) 
1.12 
(0.92,1.36) 
0.40 
Multivariate model A 1 (ref) 
1.06 
(0.86,1.30) 
1.13 
(0.91,1.40) 
1.01 
(0.81,1.27) 
1.07 
(0.84,1.36) 
0.77 
HPFS       
Median (mg/d) 850 990 1,093 1,213 1,425 
 
Cases/person-years 66 / 122,877 73 / 123,272 67 / 122,316 66 / 123,518 74 / 123,014 
 
Age-adjusted model 1 (ref) 
1.15 
(0.82,1.60) 
1.05 
(0.75,1.48) 
1.02 
(0.73,1.44) 
1.14 
(0.81,1.58) 
0.66 
Multivariate model 1 (ref) 
1.11 
(0.80,1.55) 
1.02 
(0.73,1.44) 
0.97 
(0.69,1.36) 
1.08 
(0.77,1.51) 
0.88 
Multivariate model A 1 (ref) 
1.09 
(0.78,1.53) 
0.98 
(0.69,1.40) 
0.90 
(0.63,1.31) 
1.02 
(0.69,1.49) 
0.81 
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Table 3.2. (Continued) Hazard ratios of AMD according to quintiles of cumulative average 
intake of ALA 
 
Q1 Q2 Q3 Q4 Q5 
P for 
trend 
Pooled (NHS+HPFS)       
Multivariate model 1 (ref) 
1.09 
(0.92,1.29) 
1.12 
(0.94,1.32) 
1.02 
(0.86,1.22) 
1.11 
(0.94,1.32) 
0.40 
Multivariate model A 1 (ref) 
1.07 
(0.90,1.28) 
1.09 
(0.91,1.31) 
0.98 
(0.81,1.19) 
1.06 
(0.86,1.30) 
0.88 
Multivariate model B 1 (ref) 
1.06 
(0.89,1.27) 
1.08 
(0.89,1.30) 
0.97 
(0.80,1.18) 
1.05 
(0.85,1.30) 
0.92 
Multivariate model included: age (continuous), race (Caucasian or not), BMI (<18.5, 18.5-23, 23-25, 25-
30, 30-35, ≥ 35 kg/m2), pack-years of smoking (never, 1-9, 10-24, 25-44, 45-64, ≥65y), physical activity 
(<3, 3-8.9, 9-17.9, 18-26.9, ≥27 MET-h/wk), current aspirin use (≥1 tablets/wk or none), history of 
hypertension and hypercholesterolemia, DHA (quintiles), total energy intake (quintiles). In the NHS, 
models were additionally adjusted for postmenopausal status and menopausal hormone use (never, 
current and past).    
Multivariate model A = multivariate model + LA (quintiles) 
Multivariate model B = multivariate model + LA + monounsaturated fat + saturated fat + trans fat (all in 
quintiles)
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Table 3.3. Hazard ratios of AMD according to quintiles of cumulative average intake of ALA before and after 2002 
 
Q1 Q2 Q3 Q4 Q5 P for trend P for interaction 
Intermediate AMD 
       Beginning - 2002 
          NHS ( cases n= 683) 
             Median (mg/d) 748 865 957 1,060 1,242 
        Multivariate model B 1 (ref) 1.18 (0.91,1.53) 1.00 (0.75,1.33) 1.36 (1.03,1.80) 1.33 (0.98,1.80) 0.05 
    HPFS ( cases n= 249) 
             Median (mg/d) 830 970 1,075 1,197 1,410 
        Multivariate model B 1 (ref) 1.05 (0.69,1.59) 0.90 (0.57,1.40) 1.16 (0.75,1.80) 1.50 (0.95,2.38) 0.06 
 2002 - the end 
          NHS ( cases n= 499) 
             Median (mg/d) 710 875 1,010 1,190 1,620 
        Multivariate model B 1 (ref) 0.94 (0.71,1.24) 1.10 (0.83,1.45) 0.89 (0.66,1.20) 0.85 (0.62,1.17) 0.25 
    HPFS ( cases n= 124) 
             Median (mg/d) 870 1,050 1,200 1,380 1,790 
        Multivariate model B 1 (ref) 1.05 (0.60,1.83) 1.14 (0.66,1.99) 1.23 (0.70,2.17) 0.81 (0.43,1.54) 0.57 
 Pooled (NHS + HPFS) 
          Beginning - 2002 1 (ref) 1.13 (0.91,1.41) 0.96 (0.76,1.22) 1.30 (1.03,1.64) 1.36 (1.06,1.75) 0.008 
0.003    2002 - the end 1 (ref) 0.96 (0.75,1.23) 1.12 (0.87,1.43) 0.95 (0.73,1.24) 0.85 (0.64,1.13) 0.21 
        Advanced AMD 
       Beginning - 2002 
          NHS ( cases n= 435) 
             Median (mg/d) 748 865 957 1,060 1,242 
        Multivariate model B 1 (ref) 1.17 (0.84,1.64) 1.44 (1.03,2.01) 1.10 (0.77,1.59) 1.12 (0.76,1.64) 0.91 
    HPFS ( cases n= 189) 
             Median (mg/d) 830 970 1,075 1,197 1,410 
        Multivariate model B 1 (ref) 1.01 (0.64,1.60) 1.01 (0.62,1.63) 0.97 (0.58,1.59) 1.03 (0.60,1.79) 0.96 
 2002 - the end 
          NHS ( cases n= 546) 
             Median (mg/d) 710 875 1,010 1,190 1,620 
        Multivariate model B 1 (ref) 0.78 (0.60,1.02) 0.93 (0.71,1.22) 1.07 (0.82,1.40) 0.82 (0.60,1.11) 0.54 
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Table 3.3. (Continued) Hazard ratios of AMD according to quintiles of cumulative average intake of ALA before and after 
2002 
 Q1 Q2 Q3 Q4 Q5 P for trend P for interaction 
   HPFS ( cases n=147) 
             Median (mg/d) 870 1,050 1,200 1,380 1,790 
        Multivariate model B 1 (ref) 0.69 (0.39,1.21) 1.21 (0.73,1.99) 0.83 (0.48,1.44) 0.95 (0.55,1.65) 0.93 
 Pooled (NHS + HPFS) 
          Beginning - 2002 1 (ref) 1.11 (0.85,1.46) 1.28 (0.97,1.68) 1.05 (0.78,1.41) 1.09 (0.79,1.49) 0.96 
0.14    2002 - the end 1 (ref) 0.76 (0.59,0.96) 0.98 (0.78,1.24) 1.01 (0.79,1.29) 0.84 (0.65,1.10) 0.59 
Multivariate model B was the same as in the Table 3.2 
The number of cases does not add up to the number in the Table 2 because participants missing ALA intake in 2002 were excluded from the 
analysis of post-2002 era. 
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Figure 3.1. Partial gas-liquid chromatography of trans and cis ALA isomers  
 
 
Trans ALA – A and – B denotes trans ALA with two trans bonds; ALA – C and – D denotes trans ALA 
with one trans bond. The level of trans ALA-A was extremely low and cannot always be identified in 
samples
A. Erythrocyte (collected between 1989 and 1990) 
B. Mayonnaise (samples collected before 2000) 
C. Mayonnaise (samples collected after 2000) 
ALA-B 
ALA-C   ALA-D 
cis ALA 
ALA-A
 
 ALA-B 
ALA-B 
ALA-C 
ALA-D 
cis ALA 
ALA-B 
ALA-C 
ALA-D 
cis ALA 
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Figure 3.2. The associations of primary ALA-containing foods with intermediate and advanced AMD 
 
Multivariate model included: age (continuous), race (Caucasians or not), BMI (<18.5, 18.5-23, 23-25, 25-30, 30-35, ≥ 35 kg/m2), pack-years of 
smoking (never, 1-9, 10-24, 25-44, 45-64, ≥65y), physical activity (<3, 3-8.9, 9-17.9, 18-26.9, ≥27 MET-h/wk), current aspirin use (≥1 tablets/wk 
or none), history of hypertension, history of hypercholesterolemia, and total calories (quintiles). In the NHS, models were additionally adjusted for 
postmenopausal status and menopausal hormone use (never, current and past). 
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Supplementary Tables 
 
Supplementary Table 1.1. -coefficients (standard error) for plasma carotenoid1 
multivariate linear regression models among all participants (n = 4058-4177) (adapted 
from Hendrickson et al, Nutrients 2013) 
Food
2
 
-
carot.
3
 
-carot.4 
-
crypto.
5
 
Lutein/ 
zeax.
6
 
Lycop.
7
 
Food -
carot.
8
 
Apples or pears, fresh   
0.123 
(0.024) 
   
Bananas 
0.199 
(0.032) 
     
Broccoli  
0.311 
(0.057) 
 
0.204 
(0.037) 
 
0.312 
(0.058) 
Cantaloupe  
0.360 
(0.078) 
   
0.325 
(0.080) 
Carrots, cooked 
0.427 
(0.071) 
     
Carrots, raw 
0.675 
(0.029) 
0.341 
(0.032) 
0.095 
(0.024) 
0.063 
(0.020) 
 
0.339 
(0.032) 
Corn   
-0.182 
(0.067) 
   
Eggplant/zucchini/other summer squash    
0.161 
(0.059) 
  
Eggs    
0.116 
(0.028) 
  
Grape fruit      
0.104 
(0.052) 
Juice, orange   
0.281 
(0.016) 
0.097 
(0.013) 
  
Juice, tomato     
0.249 
(0.055) 
 
Kale, mustard, or chard greens  
0.495 
(0.225) 
 
0.308 
(0.140) 
  
Lettuce, romaine or leaf  
0.164 
(0.034) 
 
0.190 
(0.021) 
 
0.168 
(0.035) 
Oranges   
0.442 
(0.032) 
0.060 
(0.024) 
  
Peaches, apricots, or plums   
0.251 
(0.041) 
   
Peas or lima beans  
-0.225 
(0.085) 
   
-0.215 
(0.086) 
Pizza  
-0.377 
(0.148) 
  
0.608 
(0.107) 
-0.368 
(0.149) 
Popcorn    
0.060 
(0.018) 
  
Prunes  
0.096 
(0.047) 
0.117 
(0.037) 
  
0.095 
(0.047) 
Spinach, cooked    
0.265 
(0.085) 
  
Spinach, raw    
0.220 
(0.076) 
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Supplementary Table 1.1.(Continued)  -coefficients (standard error) for plasma 
carotenoid
1
 multivariate linear regression models among all participants (n = 4058-4177) 
(adapted from Hendrickson et al, Nutrients 2013) 
Food
2
 
-
carot.
3
 
-carot.4 
-
crypto.
5
 
Lutein/ 
zeax.
6
 
Lycop.
7
 
Food -
carot.
8
 
Supplemental β-carotene, 1990  
0.133 
(0.017) 
    
Tomato sauce     
0.602 
(0.061) 
 
Tomatoes 
-0.061 
(0.031) 
   
0.121 
(0.024) 
 
Yams or sweet potatoes  
0.574 
(0.174) 
   
0.606 
(0.174) 
1
Plasma carotenoid concentrations were natural log transformed and adjusted for age, case-control status, body mass 
index, plasma cholesterol, menopausal status, and hormone therapy use by the residual method 
2
Foods (servings/day, milligrams/day for supplemental β-carotene) selected by stepwise selection from all foods 
contributing ≥ 0.5% to intake of the relevant carotenoid in the full cohort with 0.10 significance level to enter and 
0.05 significance level to stay 
3Intercept = 3.99, β (SE) for total energy intake = -0.0000710 (0.0000206), model adjusted R2 = 0.14 
4Intercept = 5.35, β (SE) for total energy intake = -0.0000670 (0.0000233), model adjusted R2 = 0.09 
5Intercept = 4.11, β (SE) for total energy intake = -0.0000716 (0.0000181), model adjusted R2 = 0.15 
6Intercept = 5.03, β (SE) for total energy intake = -0.0000702 (0.0000142), model adjusted R2 = 0.09 
7Intercept = 5.88, β (SE) for total energy intake = -0.0000608 (0.0000162), model adjusted R2 = 0.05 
8Intercept = 5.37, β (SE) for total energy intake = -0.0000676 (0.0000235), model adjusted R2 = 0.08 
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Supplementary Table 1.2. Hazard ratios of AMD according to quintiles of predicted plasma carotenoid scores and calculated 
intakes in the NHS 
Advanced AMD   Intermediate AMD 
Predicted plasma level 
 
¶
Calculated intake 
 
Predicted plasma level 
 
¶
Calculated 
intake 
Quintiles 
(median, 
μg/L) 
Person- 
years 
Cases Age-
adjusted  
HR 
Multivariate  
HR (95% CI) 
 Quintiles 
(median, 
ug) 
Multivariate  
HR (95% CI) 
 Cases Age-
adjusted  
HR 
Multivariate  
HR (95% CI) 
 Multivariate  
HR (95% CI) 
Lutein/Zeaxanthin 
    
  
       Q1 (152) 221,930 175 1 (Ref.) 1 (Ref.) 
 
1,408 1 (Ref.) 
 
206 1 (Ref.) 1 (Ref.) 
 
1 (Ref.) 
Q2 (161) 222,331 151 0.83 0.83 (0.66,1.03) 
 
2,098 0.84 (0.67,1.04) 
 
198 0.93 0.96 (0.78,1.16) 
 
0.82 (0.67,1.00) 
Q3 (169) 222,557 175 0.93 0.92 (0.74,1.14) 
 
2,680 0.78 (0.63,0.98) 
 
192 0.87 0.91 (0.74,1.11) 
 
0.91 (0.74,1.11) 
Q4 (179) 222,865 157 0.83 0.81 (0.64,1.01) 
 
3,389 0.72 (0.57,0.91) 
 
188 0.84 0.89 (0.72,1.09) 
 
0.93 (0.76,1.14) 
Q5 (198) 222,585 115 0.60 0.59 (0.46,0.76) 
 
4,834 0.68 (0.54,0.87) 
 
199 0.88 0.94 (0.76,1.16) 
 
0.90 (0.72,1.11) 
p for trend 
 
<.0001 <.0001 
  
0.003 
  
0.16 0.53 
 
0.73 
β-cryptoxanthin 
            Q1 (59) 221,975 150 1 (Ref.) 1 (Ref.) 
 
80 1 (Ref.) 
 
187 1 (Ref.) 1 (Ref.) 
 
1 (Ref.) 
Q2 (65) 222,325 158 0.92 0.98 (0.78,1.23) 
 
128 0.79 (0.62,0.99) 
 
170 0.81 0.86 (0.70,1.06) 
 
0.96 (0.78,1.18) 
Q3 (72) 222,623 151 0.80 0.87 (0.69,1.10) 
 
171 0.85 (0.68,1.07) 
 
214 0.94 1.02 (0.84,1.25) 
 
1.01 (0.82,1.24) 
Q4 (89) 222,625 172 0.84 0.94 (0.75,1.17) 
 
218 0.82 (0.66,1.03) 
 
204 0.83 0.93 (0.76,1.14) 
 
0.93 (0.76,1.15) 
Q5 (93) 222,720 142 0.64 0.74 (0.58,0.93) 
 
297 0.70 (0.55,0.88) 
 
208 0.79 0.92 (0.75,1.13) 
 
0.98 (0.79,1.20) 
p for trend 
 
0.0001 0.01 
  
0.009 
  
0.04 0.66 
 
0.79 
Lycopene 
            Q1 (354) 222,439 203 1 (Ref.) 1 (Ref.) 
 
3,322 1 (Ref.) 
 
264 1 (Ref.) 1 (Ref.) 
 
1 (Ref.) 
Q2 (370) 222,454 173 1.03 1.01 (0.82,1.24) 
 
4,693 1.05 (0.85,1.29) 
 
205 0.92 0.92 (0.77,1.11) 
 
1.01 (0.84,1.21) 
Q3 (383) 222,524 147 1.01 0.98 (0.79,1.21) 
 
5,814 1.03 (0.84,1.28) 
 
190 0.97 0.97 (0.80,1.17) 
 
0.93 (0.76,1.13) 
Q4 (400) 222,622 124 0.95 0.91 (0.72,1.14) 
 
7,205 0.76 (0.60,0.97) 
 
158 0.88 0.88 (0.72,1.08) 
 
1.01 (0.83,1.23) 
Q5 (438) 222,229 126 1.10 1.04 (0.82,1.30) 
 
9,909 1.04 (0.83,1.29) 
 
166 1.04 1.03 (0.84,1.25) 
 
1.05 (0.86,1.28) 
p for trend 
 
0.57 0.99 
  
0.60 
  
0.80 0.88 
 
0.61 
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Supplementary Table 1.2. (Continued) Hazard ratios of AMD according to quintiles of predicted plasma carotenoid scores and 
calculated intakes in the NHS 
α-carotene 
            Q1 (51) 221,588 163 1 (Ref.) 1 (Ref.) 
 
323 1 (Ref.) 
 
191 1 (Ref.) 1 (Ref.) 
 
1 (Ref.) 
Q2 (55) 222,435 174 0.93 0.99 (0.79,1.22) 
 
507 0.72 (0.58,0.91) 
 
190 0.88 0.92 (0.75,1.13) 
 
1.00 (0.81,1.23) 
Q3 (58) 222,649 156 0.76 0.83 (0.66,1.04) 
 
681 0.81 (0.65,1.01) 
 
204 0.87 0.94 (0.77,1.16) 
 
1.07 (0.87,1.33) 
Q4 (65) 222,787 154 0.74 0.82 (0.65,1.03) 
 
932 0.81 (0.65,1.01) 
 
184 0.77 0.85 (0.69,1.05) 
 
1.18 (0.96,1.45) 
Q5 (79) 222,810 126 0.57 0.64 (0.50,0.82)  
1,429 0.61 (0.48,0.77) 
 
214 0.84 0.96 (0.78,1.18) 
 
1.05 (0.85,1.30) 
p for trend 
 
<.0001 0.0001 
  
0.0007 
  
0.12 0.80 
 
0.51 
β-carotene 
            Q1 (198) 221,515 145 1 (Ref.) 1 (Ref.) 
 
2,278 1 (Ref.) 
 
175 1 (Ref.) 1 (Ref.) 
 
1 (Ref.) 
Q2 (215) 222,388 167 1.00 1.01 (0.81,1.27) 
 
3,312 1.07 (0.85,1.34) 
 
192 0.95 0.97 (0.79,1.20) 
 
1.05 (0.85,1.29) 
Q3 (231) 222,589 164 0.92 0.96 (0.76,1.21) 
 
4,220 1.07 (0.84,1.34) 
 
210 0.98 1.03 (0.84,1.27) 
 
1.12 (0.90,1.38) 
Q4 (254) 222,858 139 0.74 0.78 (0.61,1.00) 
 
5,353 0.84 (0.65,1.08) 
 
190 0.85 0.92 (0.74,1.15) 
 
1.10 (0.89,1.36) 
Q5 (315) 222,917 158 0.83 0.88 (0.69,1.13) 
 
7,584 0.86 (0.66,1.11) 
 
216 0.94 1.04 (0.83,1.29) 
 
1.02 (0.81,1.28) 
p for trend 
 
0.02 0.15 
  
0.05 
  
0.49 0.74 
 
0.97 
β-carotene from food 
           Q1 (200) 214,856 151 1 (Ref.) 1 (Ref.) 
 
2,151 1 (Ref.) 
 
170 1 (Ref.) 1 (Ref.) 
 
1 (Ref.) 
Q2 (215) 214,310 160 0.91 0.90 (0.72,1.13) 
 
3,092 0.98 (0.78,1.24) 
 
179 0.91 0.93 (0.75,1.16) 
 
0.84 (0.68,1.04) 
Q3 (229) 212,920 147 0.78 0.78 (0.61,0.99) 
 
3,913 0.91 (0.72,1.15) 
 
191 0.91 0.96 (0.77,1.19) 
 
0.98 (0.80,1.21) 
Q4 (248) 211,231 151 0.78 0.78 (0.61,0.99) 
 
4,907 0.78 (0.61,0.99) 
 
185 0.86 0.94 (0.75,1.17) 
 
0.97 (0.78,1.20) 
Q5 (289) 208,284 135 0.66 0.66 (0.51,0.85) 
 
6,759 0.66 (0.51,0.85) 
 
205 0.91 1.02 (0.81,1.28) 
 
0.91 (0.73,1.14) 
p for trend 
 
0.0003 0.001 
  
0.0002 
  
0.44 0.69 
 
0.80 
Total carotene from food 
           Q1 (253) 214,758 152 1 (Ref.) 1 (Ref.) 
 
2,668 1 (Ref.) 
 
175 1 (Ref.) 1 (Ref.) 
 
1 (Ref.) 
Q2 (271) 214,258 170 0.94 0.94 (0.75,1.18) 
 
3,865 1.05 (0.83,1.31) 
 
174 0.84 0.87 (0.70,1.08) 
 
0.90 (0.73,1.12) 
Q3 (289) 213,028 140 0.73 0.73 (0.58,0.93) 
 
4,927 0.91 (0.72,1.15) 
 
201 0.92 0.98 (0.79,1.21) 
 
1.08 (0.87,1.32) 
Q4 (313) 210,987 146 0.73 0.74 (0.58,0.95) 
 
6,274 0.75 (0.59,0.96) 
 
175 0.78 0.85 (0.68,1.06) 
 
0.95 (0.77,1.18) 
Q5 (366) 208,570 136 0.65 0.66 (0.51,0.86) 
 
8,855 0.70 (0.54,0.90) 
 
205 0.87 0.98 (0.79,1.23) 
 
0.99 (0.79,1.23) 
p for trend 
 
<.0001 0.001 
  
0.0003 
  
0.29 0.83 
 
0.95 
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Supplementary Table 1.2. (Continued) Hazard ratios of AMD according to quintiles of predicted plasma carotenoid scores and 
calculated intakes in the NHS 
§
Total carotenoid index 
           Q1 (9) 222,083 174 1 (Ref.) 1 (Ref.) 
 
8 1 (Ref.) 
 
218 1 (Ref.) 1 (Ref.) 
 
1 (Ref.) 
Q2 (12) 221,393 172 0.95 0.97 (0.78,1.20) 
 
12 0.89 (0.71,1.11) 
 
166 0.73 0.76 (0.62,0.93) 
 
0.98 (0.80,1.21) 
Q3 (15) 234,719 160 0.79 0.81 (0.65,1.01) 
 
15 0.75 (0.60,0.94) 
 
214 0.84 0.90 (0.74,1.09) 
 
1.00 (0.81,1.22) 
Q4 (18) 208,544 137 0.74 0.77 (0.61,0.97) 
 
18 0.77 (0.61,0.96) 
 
177 0.77 0.84 (0.68,1.03) 
 
1.08 (0.88,1.33) 
Q5  (21) 225,528 130 0.64 0.67 (0.53,0.86) 
 
22 0.69 (0.55,0.87) 
 
208 0.81 0.92 (0.75,1.13) 
 
1.03 (0.83,1.26) 
p for trend   <.0001 0.0003     0.001     0.09 0.76   0.60 
Multivariate models were adjusted for: age (continuous), BMI (<18.5, 18.5-23, 23-25, 25-30, 30-35, ≥ 35 kg/m2), pack-years of smoking (never, 1-9, 10-24, 25-
44, 45-64, ≥65y), physical activity (<3, 3-8.9, 9-17.9, 18-26.9, ≥27 MET-h/wk), current aspirin use (≥1 tablets/wk or none), history of hypertension, diabetes and 
cardiovascular diseases, postmenopausal status and menopausal hormone use (never, current and past), dietary variables including aHEI (excluding fruits and 
vegetables), alcohol intake, DHA and ALA (all in quintiles). 
§
 Total carotenoid index was created by summing the quintile score of each carotenoid. 
¶
 Models were additionally adjusted for total calorie intake (in quintiles).
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Supplementary Table 1.3. Hazard ratios of AMD according to quintiles of predicted plasma carotenoid scores and calculated 
intakes in the HPFS 
Advanced AMD   Intermediate AMD 
Predicted plasma level 
 
Calculated intake 
 
Predicted plasma level 
 
Calculated 
intake 
Quintiles 
(median, 
μg/L) 
Person- 
years 
Cases Age-
adjusted  
HR 
Multivariate  
HR (95% CI) 
 Quintiles 
(median, 
ug) 
Multivariate  
HR (95% CI) 
 Case
s 
Age-
adjusted  
HR 
Multivariate  
HR (95% CI) 
 Multivariate  
HR (95% CI) 
Lutein/Zeaxanthin 
   
  
       Q1 (151) 98,632 78 1(Ref.) 1(Ref.) 
 
1,511 1(Ref.) 
 
72 1(Ref.) 1(Ref.) 
 
1(Ref.) 
Q2 (161) 99,238 65 0.76 0.81 (0.58,1.13) 
 
2,313 1.05 (0.75,1.47) 
 
72 0.94 1.01 (0.72,1.40) 
 
1.27 (0.92,1.76) 
Q3 (169) 99,631 79 0.92 0.98 (0.71,1.35) 
 
3,012 1.06 (0.75,1.49) 
 
79 1.00 1.07 (0.77,1.48) 
 
1.13 (0.81,1.58) 
Q4 (180) 99,764 73 0.82 0.88 (0.63,1.23) 
 
3,864 1.06 (0.75,1.50) 
 
81 0.98 1.04 (0.75,1.44) 
 
1.06 (0.75,1.50) 
Q5 (203) 99,651 50 0.53 0.59 (0.41,0.86) 
 
5,629 1.08 (0.75,1.55) 
 
74 0.86 0.92 (0.66,1.30) 
 
1.20 (0.84,1.70) 
p for trend 
 
0.001 0.01 
  
0.71 
  
0.41 0.62 
 
0.65 
β-cryptoxanthin 
            Q1 (58) 98,452 67 1(Ref.) 1(Ref.) 
 
82 1(Ref.) 
 
71 1(Ref.) 1(Ref.) 
 
1(Ref.) 
Q2 (65) 99,347 63 0.80 0.87 (0.61,1.23) 
 
141 0.94 (0.67,1.34) 
 
69 0.84 0.90 (0.64,1.26) 
 
0.98 (0.71,1.36) 
Q3 (72) 99,481 72 0.78 0.86 (0.61,1.21) 
 
194 0.90 (0.63,1.26) 
 
82 0.86 0.93 (0.67,1.29) 
 
0.90 (0.65,1.25) 
Q4 (80) 99,868 74 0.72 0.82 (0.58,1.15) 
 
253 0.88 (0.62,1.25) 
 
83 0.77 0.87 (0.62,1.20) 
 
0.83 (0.59,1.16) 
Q5 (99) 99,767 69 0.62 0.73 (0.51,1.04) 
 
358 0.75 (0.52,1.07) 
 
73 0.62 0.70 (0.50,0.99) 
 
0.72 (0.51,1.01) 
p for trend 
 
0.006 0.09 
  
0.10 
  
0.004 0.04 
 
0.03 
Lycopene 
            Q1 (346) 99,214 115 1(Ref.) 1(Ref.) 
 
3,259 1(Ref.) 
 
105 1(Ref.) 1(Ref.) 
 
1(Ref.) 
Q2 (364) 99,328 82 0.91 0.94 (0.70,1.25) 
 
5,079 0.96 (0.71,1.29) 
 
79 0.96 1.01 (0.75,1.36) 
 
0.92 (0.68,1.24) 
Q3 (379) 99,617 61 0.81 0.84 (0.61,1.15) 
 
6,609 0.84 (0.60,1.16) 
 
74 1.07 1.13 (0.83,1.53) 
 
1.11 (0.82,1.50) 
Q4 (400) 99,563 47 0.71 0.74 (0.52,1.04) 
 
8,599 0.79 (0.56,1.12) 
 
65 1.08 1.13 (0.83,1.55) 
 
1.13 (0.82,1.55) 
Q5 (450) 99,195 40 0.69 0.70 (0.49,1.02) 
 
12,589 0.93 (0.66,1.30) 
 
55 1.04 1.07 (0.76,1.49) 
 
1.04 (0.75,1.45) 
p for trend 
 
0.02 0.03 
  
0.46 
  
0.65 0.58 
 
0.56 
             
             
             
 104 
 
Supplementary Table 1.3. (Continued) Hazard ratios of AMD according to quintiles of predicted plasma carotenoid scores and 
calculated intakes in the HPFS 
α-carotene 
            Q1 (50) 98,248 60 1(Ref.) 1(Ref.) 
 
345 1(Ref.) 
 
77 1(Ref.) 1(Ref.) 
 
1(Ref.) 
Q2 (54) 99,174 67 0.94 1.00 (0.70,1.43) 
 
551 1.02 (0.73,1.43) 
 
59 0.67 0.75 (0.53,1.06) 
 
0.81 (0.58,1.13) 
Q3 (58) 99,716 79 1.03 1.16 (0.82,1.64) 
 
753 0.84 (0.59,1.20) 
 
70 0.70 0.83 (0.59,1.15) 
 
0.67 (0.47,0.95) 
Q4 (65) 99,752 76 0.91 1.05 (0.74,1.49) 
 
1,069 0.85 (0.60,1.20) 
 
82 0.78 0.92 (0.66,1.27) 
 
1.04 (0.76,1.42) 
Q5 (82) 100,026 63 0.67 0.80 (0.55,1.15) 
 
1,713 0.88 (0.62,1.25) 
 
90 0.75 0.89 (0.64,1.23) 
 
0.83 (0.60,1.15) 
p for trend 
 
0.01 0.12 
  
0.41 
  
0.43 0.95 
 
0.85 
β-carotene 
            Q1 (192) 98,210 69 1(Ref.) 1(Ref.) 
 
2,439 1(Ref.) 
 
58 1(Ref.) 1(Ref.) 
 
1(Ref.) 
Q2 (210) 99,137 73 0.81 0.88 (0.63,1.22) 
 
3,666 1.00 (0.72,1.39) 
 
75 1.05 1.15 (0.81,1.63) 
 
0.85 (0.60,1.19) 
Q3 (228) 99,549 66 0.69 0.77 (0.54,1.10) 
 
4,782 0.74 (0.52,1.06) 
 
83 1.06 1.23 (0.87,1.74) 
 
1.03 (0.75,1.43) 
Q4 (256) 99,826 76 0.71 0.83 (0.59,1.18) 
 
6,257 0.89 (0.63,1.26) 
 
87 1.00 1.19 (0.84,1.69) 
 
0.84 (0.60,1.19) 
Q5 (351) 100,195 61 0.58 0.69 (0.48,1.00) 
 
9,409 0.86 (0.59,1.24) 
 
75 0.85 1.00 (0.69,1.45) 
 
0.93 (0.65,1.31) 
p for trend 
 
0.005 0.08 
  
0.44 
  
0.18 0.58 
 
0.78 
β-carotene from food 
           Q1 (194) 90,917 66 1(Ref.) 1(Ref.) 
 
2,273 1(Ref.) 
 
55 1(Ref.) 1(Ref.) 
 
1(Ref.) 
Q2 (209) 90,665 53 0.64 0.69 (0.47,0.99) 
 
3,362 0.95 (0.67,1.35) 
 
55 0.82 0.90 (0.62,1.31) 
 
0.92 (0.64,1.32) 
Q3 (223) 90,047 71 0.76 0.85 (0.60,1.21) 
 
4,315 0.86 (0.60,1.24) 
 
65 0.86 0.99 (0.68,1.43) 
 
0.90 (0.62,1.30) 
Q4 (242) 88,893 72 0.69 0.81 (0.57,1.16) 
 
5,502 1.06 (0.74,1.51) 
 
83 1.02 1.20 (0.83,1.72) 
 
1.13 (0.79,1.60) 
Q5 (285) 86,289 55 0.49 0.60 (0.40,0.88) 
 
7,758 0.75 (0.50,1.11) 
 
82 0.89 1.04 (0.71,1.51) 
 
0.94 (0.65,1.36) 
p for trend 
 
0.0008 0.04 
  
0.24 
  
0.93 0.51 
 
0.93 
Total carotene from food 
          Q1 (246) 90,945 65 1(Ref.) 1(Ref.) 
 
2,728 1(Ref.) 
 
57 1(Ref.) 1(Ref.) 
 
1(Ref.) 
Q2 (265) 90,639 59 0.71 0.78 (0.54,1.12) 
 
4,030 0.80 (0.56,1.15) 
 
57 0.81 0.91 (0.62,1.32) 
 
0.79 (0.55,1.13) 
Q3 (282) 89,870 68 0.72 0.83 (0.58,1.18) 
 
5,241 0.86 (0.61,1.23) 
 
58 0.74 0.86 (0.59,1.25) 
 
0.74 (0.52,1.06) 
Q4 (307) 88,928 72 0.70 0.83 (0.58,1.18) 
 
6,823 0.84 (0.59,1.20) 
 
87 1.03 1.22 (0.85,1.74) 
 
0.99 (0.71,1.40) 
Q5 (364) 86,430 53 0.48 0.58 (0.39,0.87) 
 
10,034 0.78 (0.53,1.13) 
 
81 0.84 1.00 (0.68,1.44) 
 
0.82 (0.57,1.18) 
p for trend 
 
0.0003 0.02 
  
0.29 
  
0.87 0.60 
 
0.76 
             
 105 
 
Supplementary Table 1.3. (Continued) Hazard ratios of AMD according to quintiles of predicted plasma carotenoid scores and 
calculated intakes in the HPFS 
Total carotenoid index 
           Q1 (9) 96,159 72 1(Ref.) 1(Ref.) 
 
8 1(Ref.) 
 
73 1(Ref.) 1(Ref.) 
 
1(Ref.) 
Q2 (12) 98,756 74 0.87 0.92 (0.66,1.28) 
 
18 0.70 (0.49,1.00) 
 
61 0.73 0.80 (0.57,1.12) 
 
0.87 (0.62,1.21) 
Q3 (15) 108,051 84 0.84 0.93 (0.67,1.28) 
 
15 0.99 (0.72,1.36) 
 
90 0.91 1.03 (0.75,1.42) 
 
0.91 (0.66,1.26) 
Q4 (18) 96,109 64 0.68 0.78 (0.55,1.11) 
 
18 0.84 (0.60,1.18) 
 
76 0.81 0.94 (0.67,1.32) 
 
1.02 (0.74,1.40) 
Q5  (21) 97,841 51 0.52 0.61 (0.42,0.89) 
 
22 0.80 (0.56,1.12) 
 
78 0.78 0.93 (0.66,1.31) 
 
0.91 (0.66,1.27) 
p for trend   0.0001 0.009    
0.36     0.29 0.99   0.85 
Multivariate models were adjusted for the same variables as the Supplementary Table 1.1 except postmenopausal status and hormone use and 
additionally adjusted for race (Caucasian v.s. non-Caucasian)
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Supplementary Table 1.4. Association of first diagnosis of AMD with change in intakes of carotenoids and other nutrients 
  
All (n=422) 
 
Intermediate (n=198) 
 
Advanced (n=224) 
  
Point Estimate  95% CI  P value 
 
Point Estimate  95% CI  P value 
 
Point Estimate  95% CI  P value 
Lutein/zeaxanthin, μg 
          β2 (AMD) 
 
204 (42, 366) 0.01 
 
93 (-143, 330) 0.44 
 
315 (93, 538) 0.006 
β3 (AMD*interval) 
 
63 (0.83, 126) 0.05 
 
38 (-48, 124) 0.39 
 
93 (3, 183) 0.04 
α-carotene, μg 
            β2 (AMD) 
 
0.09 (-67.2, 67.4) 0.99 
 
-21 (-114, 71) 0.66 
 
18 (-76, 115) 0.69 
β3 (AMD*interval) 
 
-0.23 (-28, 27.6) 0.99 
 
3 (-43, 49) 0.9 
 
-2.6 (-32, 27) 0.86 
β-carotene , μg 
            β2 (AMD) 
 
315.7 (-4.6, 636) 0.05 
 
394 (-45, 832) 0.08 
 
254 (-214, 722) 0.29 
β3 (AMD*interval) 
 
6.7 (-122, 135) 0.92 
 
-59 (-250, 132) 0.55 
 
70 (-103, 244) 0.43 
β-carotene from food, μg 
          β2 (AMD) 
 
-23 (-235, 188) 0.83 
 
-104 (-388, 181) 0.48 
 
56 (-250, 362) 0.72 
β3 (AMD*interval) 
 
73 (-18, 164) 0.11 
 
59 (-78, 195) 0.4 
 
92 (-26, 209) 0.13 
β-cryptoxanthin, μg 
          β2 (AMD) 
 
2.6 (-7.3, 12.5) 0.61 
 
0.49 (-13, 14) 0.94 
 
4.4 (-10, 19) 0.54 
β3 (AMD*interval) 
 
-0.67 (-4.7, 3.3) 0.74 
 
0.34 (-4.8, 5.5) 0.9 
 
-1.6 (-7.8, 4.6) 0.61 
Lycopene, μg 
            β2 (AMD) 
 
72 (-253, 397) 0.67 
 
167 (-266, 599) 0.45 
 
-26 (-510, 459) 0.92 
β3 (AMD*interval) 
 
42 (-87, 170) 0.53 
 
76 (-105, 257) 0.41 
 
2.4 (-180, 185) 0.98 
Total fruits and vegetables, servings   
        β2 (AMD) 
 
-0.17 (-0.33, 0.003) 0.05 
 
0.17 (-0.40, 0.06) 0.15 
 
-0.17 (-0.41, 0.08) 0.18 
β3 (AMD*interval) 
 
0.08 (0.01, 0.14) 0.02 
 
0.10 (0.02, 0.19) 0.02 
 
0.05 (-0.05, 0.15) 0.32 
DHA, mg 
            β2 (AMD) 
 
-11 (-24, 3) 0.11 
 
-12 (-28, 4) 0.13 
 
-10 (-30, 11) 0.35 
β3 (AMD*interval) 
 
9 (3, 15) 0.003 
 
13 (6, 21) <.001 
 
4 (-5, 13) 0.35 
ALA, mg 
            β2 (AMD) 
 
-10 (-500, 30) 0.58 
 
-26 (-8, 25) 0.32 
 
3 (-56, 62) 0.92 
β3 (AMD*interval)   30 (12, 40) <.001   32 (13, 51) 0.001   20 (-11, 50) 0.06 
β2= Change in calorie-adjusted carotenoid intake associated with a diagnosis of AMD during the middle of follow-up 
β3= Difference in the rate of change in calorie-adjusted carotenoid intake comparing AMD patients to non-AMD participants
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Supplementary Table 2.1. Empirical prediction models for the measured plasma and erythrocyte EPA and DHA  
 
NHS 
 
HPFS 
 
Food (servings/d) Cohort
ǂ
, % β SE p 
 
  Food (servings/d) Cohort
§
, % β SE p 
EPA 
     
       
Erythrocyte
¶
 Canned tuna 17.9 0.23 0.07 <.001  
Erythrocyte
¶
 Canned tuna 10.2 0.37 0.08 <.001 
(Mean ± SD) Dark fish 38.2 1.27 0.16 <.001  
(Mean ± SD) Dark fish 43.4 1.33 0.11 <.001 
(0.41 ± 0.16 %) Other fish 20.0 0.23 0.08 0.003  
(0.46 ± 0.25%) Other fish 13.8 0.74 0.11 <.001 
n=1,557 Shrimp and shellfish 8.2 0.69 0.18 <.001  
n=1,364 
  
   
 
Chicken w/ skin 12.1 0.17 0.07 0.01     
   
 
R
2
  = 0.09             R
2
  = 0.19         
   
   
       
Plasma
¶
 Canned tuna 17.9 0.20 0.10 0.040  
Plasma
¶
 Canned tuna 10.2 0.48 0.10 <.001 
(Mean ± SD) Dark fish 38.2 1.13 0.22 <.001  
(Mean ± SD) Dark fish 43.4 1.21 0.14 <.001 
(0.45 ± 0.23%) Other fish 20.0 0.25 0.11   0.02  
(0.54 ± 0.37%) Other fish 13.8 0.78 0.14 <.001 
n=1,353 Shrimp and shellfish 8.2 0.66 0.25 0.009  
n=1,321 
  
   
 
R
2
  = 0.05             R
2
  = 0.14         
   
   
       
DHA 
            
Erythrocyte
¶
 Canned tuna 29.1 0.40 0.05 <.001  
Erythrocyte
¶
 Canned tuna 19.8 0.42 0.06 <.001 
(Mean ± SD) Dark fish 22.3 1.23 0.11 <.001  
(Mean ± SD) Dark fish 29.5 0.90 0.08 <.001 
(3.29 ± 0.98%) Other fish 26.4 0.40 0.06 <.001  
(3.32 ± 1.11%) Other fish 23.2 0.60 0.08 <.001 
n=1,966 Shrimp and shellfish 3.2 0.34 0.13 0.007  
n=1,365 Chicken w/o skin 8.7 0.09 0.04   0.03 
   
   
  
       R
2
  = 0.17             R
2
  = 0.25         
Plasma
¶
 Canned tuna 29.1 0.38 0.06 <.001  
Plasma
¶
 Canned tuna 19.8 0.59 0.07 <.001 
(Mean ± SD) Dark fish 22.3 1.40 0.15 <.001  
(Mean ± SD) Dark fish 29.5 1.05 0.09 <.001 
(1.42 ± 0.58%) Other fish 26.4 0.46 0.07 <.001  
(1.37 ± 0.60%) Other fish 23.2 0.66 0.10 <.001 
n=1,766 Shrimp and shellfish 3.2 0.46 0.17 0.007  
n=1,319 
 
 
 
    R
2
  = 0.14             R
2
  = 0.24         
 
 108 
 
Supplementary Table 2.1. (Continued) Empirical prediction models for the measured plasma and erythrocyte EPA and DHA  
ǂ
 1986-1990 average percent contribution to total intake in the NHS full cohort 
§
 1990-1994 average percent contribution to total intake in the HPFS full cohort 
¶
 Mean level was expressed as the percentage of total fatty acids; biomarker concentrations were adjusted for age, BMI, pack-year of smoking, 
fasting status, case-control status, menopausal status and hormone use 
¶
 Total calories were forced into all models.
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Supplementary Table 2.2. The Spearman correlations with measured EPA and DHA levels 
for dietary intake and predicted biomarker scores in the NHS and HPFS 
 
 
 
Predicted 
 
 
 
Predicted 
 
n Diet Erythrocyte 
 
n Diet Plasma 
NHS  
   
 
  EPA 1,557 0.28 0.30 
 
1,353 0.19 0.21 
DHA 1,966 0.44 0.45 
 
1,766 0.39 0.40 
HPFS  
   
 
  EPA 1,364 0.50 0.46 
 
1,321 0.42 0.38 
DHA 1,365 0.56 0.53 
 
1,319 0.53 0.51 
P<.0001 for all the correlation coefficients 
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Supplementary Table 2.3. The multivariate hazard ratios of AMD according to dietary 
intake, predicted erythrocyte and plasma scores of EPA and DHA among non-users of fish 
oil supplements in the NHS and HPFS 
        HR comparing the top to the bottom quintile 
 
 
  
DHA p trend 
 
EPA 
p 
trend 
Intermediate AMD 
  
     
 
NHS Diet 
 
0.75 (0.61,0.92) 0.01 
 
0.88 (0.71,1.08) 0.17 
  
Erythrocyte 
 
0.79 (0.64,0.98) 0.04 
 
0.79 (0.64,0.97) 0.04 
  
Plasma 
 
0.76 (0.62,0.94) 0.04 
 
0.79 (0.65,0.97) 0.06 
         
 
HPFS Diet 
 
0.88 (0.62,1.25) 0.48 
 
0.94 (0.66,1.33) 0.56 
  
Erythrocyte 
 
0.70 (0.50,0.97) 0.02 
 
0.76 (0.54,1.05) 0.06 
  
Plasma 
 
0.74 (0.53,1.03) 0.03 
 
0.72 (0.52,0.99) 0.03 
Advanced AMD 
       
         
 
NHS Diet 
 
1.05 (0.84,1.31) 0.89 
 
1.14 (0.91,1.43) 0.18 
  
Erythrocyte 
 
1.09 (0.87,1.37)* 0.70 
 
1.12 (0.90,1.40)* 0.22 
  
Plasma 
 
1.17 (0.94,1.47)* 0.27 
 
1.11 (0.89,1.38)* 0.25 
         
 
HPFS Diet 
 
0.75 (0.51,1.09) 0.12 
 
0.86 (0.58,1.25) 0.51 
  
Erythrocyte 
 
0.54 (0.37,0.80)* 0.003 
 
0.57 (0.39,0.85)* 0.008 
    Plasma   0.55 (0.37,0.81)* 0.005   0.56 (0.38,0.83)* 0.003 
*p for heterogeneity in the HR between the NHS and HPFS was < 0.05 
Multivariate models were adjusted for the same variables as in the Table 2.2. 
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Supplementary Table 2.4. The multivariate hazard ratios of AMD stratified by the median 
intake of linoleic acid 
    HR comparing Q5 to Q1   
  
 
Low LA p trend 
 
High LA p trend p interaction 
Intermediate AMD 
      EPA NHS 0.96 (0.73,1.25) 0.39 
 
0.82 (0.64,1.07) 0.15 0.57 
 
HPFS 1.02 (0.64,1.61) 0.94 
 
0.77 (0.49,1.21) 0.16 0.89 
 
pooled 0.99 (0.78,1.24) 0.61 
 
0.80 (0.64,1.00) 0.04 0.51 
        DHA NHS 0.78 (0.60,1.03) 0.09 
 
0.76 (0.58,0.98) 0.04 0.38 
 
HPFS 1.00 (0.63,1.61) 0.73 
 
0.72 (0.46,1.11) 0.17 0.27 
 
pooled 0.84 (0.67,1.07) 0.15 
 
0.74 (0.59,0.92) 0.01 0.18 
        EPA + DHA NHS 0.84 (0.64,1.09) 0.15 
 
0.78 (0.61,1.01) 0.10 0.74 
 
HPFS 1.08 (0.68,1.71) 0.88 
 
0.76 (0.49,1.19) 0.15 0.48 
 
pooled 0.91 (0.72,1.14) 0.26 
 
0.77 (0.62,0.96) 0.02 0.54 
        EPA + DHA NHS 0.90 (0.69,1.18) 0.53 
 
0.80 (0.61,1.05) 0.07 0.59 
(supplements users HPFS 0.97 (0.59,1.59) 0.59 
 
0.78 (0.49,1.24) 0.14 0.87 
excluded) pooled 0.93 (0.73,1.18) 0.44 
 
0.79 (0.63,1.00) 0.02 0.42 
        Advanced AMD 
      EPA NHS 0.99 (0.74,1.33) 0.80 
 
1.19 (0.89,1.58) 0.14 0.58 
 
HPFS 1.02 (0.67,1.57) 0.26 
 
0.72 (0.43,1.20) 0.20 0.10 
 
pooled 1.01 (0.79,1.28) 0.54 
 
1.04 (0.81,1.33) 0.98 0.99 
        DHA NHS 1.00 (0.75,1.33) 0.55 
 
1.10 (0.82,1.48) 0.58 0.73 
 
HPFS 0.90 (0.58,1.40) 0.82 
 
0.74 (0.46,1.20) 0.14 0.32 
 
pooled 0.97 (0.76, 1.23) 0.77 
 
0.98 (0.76, 1.26) 0.49 0.96 
        EPA + DHA NHS 1.05 (0.78,1.41) 0.71 
 
1.21 (0.91,1.61) 0.28 0.70 
 
HPFS 0.96 (0.61,1.50) 0.65 
 
0.73 (0.44,1.21) 0.12 0.17 
 
pooled 1.03 (0.80,1.32) 0.97 
 
1.06 (0.82,1.35) 0.72 0.98 
        EPA + DHA NHS 0.99 (0.73,1.34) 0.64 
 
1.19 (0.88,1.61) 0.21 0.60 
(supplements users HPFS 0.75 (0.46,1.20) 0.51 
 
0.47 (0.25, 0.86) 0.007 0.07 
excluded) pooled 0.91 (0.71,1.18) 0.44 
 
0.97 (0.74, 1.26) 0.31 0.93 
The median intake of LA was 8.9 g/d in the NHS  and 11g/d in the HPFS 
Multivariate models were adjusted for the same variables as in the Table 2.2. 
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Supplementary Table 2.5. The multivariate hazard ratios of AMD stratified by the median 
age of onset of AMD cases 
    HR comparing Q5 to Q1   
    age<73  p trend   age>=73 p trend p interaction 
Intermediate AMD 
      EPA NHS 0.80 (0.63,1.02) 0.10 
 
0.99 (0.73,1.33) 0.52 0.16 
 
HPFS 1.09 (0.64,1.85) 0.87 
 
0.75 (0.51,1.11) 0.21 0.34 
 
pooled 0.85 (0.68,1.05) 0.16 
 
0.91 (0.72,1.15) 0.18 0.51 
        DHA NHS 0.65 (0.51,0.83) 0.005 
 
0.95 (0.71,1.27) 0.38 0.09 
 
HPFS 0.99 (0.60,1.64) 0.49 
 
0.71 (0.48,1.06) 0.27 0.02 
 
pooled 0.70 (0.57,0.87) 0.006 
 
0.87 (0.69,1.10) 0.16 0.64 
        EPA + DHA NHS 0.68 (0.54,0.87) 0.10 
 
1.00 (0.75,1.33) 0.72 0.25 
 
HPFS 1.09 (0.65,1.83) 0.54 
 
0.77 (0.52,1.14) 0.27 0.12 
 
pooled 0.74 (0.60,0.92) 0.01 
 
0.92 (0.73,1.16) 0.30 0.64 
        EPA + DHA NHS 0.71 (0.56,0.91) 0.02 
 
1.06 (0.79,1.43) 0.92 0.26 
(supplements users HPFS 1.02 (0.60,1.75) 0.59 
 
0.72 (0.47,1.10) 0.11 0.07 
excluded) pooled 0.76 (0.61,0.95) 0.02 
 
0.95 (0.74,1.20) 0.29 0.52 
        Advanced AMD 
      EPA NHS 0.92 (0.69,1.22) 0.49 
 
1.17 (0.87,1.57) 0.20 0.02 
 
HPFS 0.84 (0.49,1.43) 0.82 
 
0.95 (0.64,1.42) 0.98 0.54 
 
pooled 0.92 (0.72,1.19) 0.63 
 
1.10 (0.87,1.39) 0.39 0.21 
        DHA NHS 0.88 (0.65,1.17) 0.14 
 
1.14 (0.86,1.53) 0.46 0.14 
 
HPFS 0.82 (0.49,1.37) 0.55 
 
0.82 (0.55,1.23) 0.44 0.99 
 
pooled 0.88 (0.68,1.13) 0.18 
 
1.04 (0.82,1.32) 0.99 0.31 
        EPA + DHA NHS 0.92 (0.69,1.24) 0.21 
 
1.24 (0.93,1.66) 0.20 0.11 
 
HPFS 0.80 (0.47,1.37) 0.63 
 
0.89 (0.59,1.35) 0.50 0.83 
 
pooled 0.91 (0.71,1.18) 0.29 
 
1.13 (0.89,1.43) 0.68 0.44 
        EPA + DHA NHS 0.99 (0.73,1.33) 0.49 
 
1.09 (0.80,1.48) 0.40 0.07 
(supplements users HPFS 0.54 (0.29,0.99) 0.09 
 
0.67 (0.42,1.06) 0.05 0.68 
excluded) pooled 0.90 (0.69,1.17) 0.16   0.94 (0.73,1.22) 0.44 0.47 
Multivariate models were adjusted for the same variables as in the Table2.2 
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Supplementary Table 3.1. The associations between intake of ALA and AMD stratified by smoking status 
 
No. of cases Q1 Q2 Q3 Q4 Q5 p trend p interaction 
Intermediate AMD 
        NHS 
        Never smokers 528 1 (ref) 1.30 (0.97,1.75) 1.23 (0.90,1.68) 1.40 (1.02,1.93) 1.69 (1.20,2.37) 0.003 0.08 
Ever smokers 681 1 (ref) 1.15 (0.90,1.48) 0.93 (0.71,1.23) 1.37 (1.05,1.79) 1.10 (0.81,1.48) 0.43 
 HPFS 
        Never smokers 150 1 (ref) 1.38 (0.80,2.37) 1.21 (0.68,2.16) 1.52 (0.86,2.69) 1.61 (0.88,2.93) 0.14 
 Ever smokers 230 1 (ref) 0.89 (0.59,1.35) 0.78 (0.51,1.21) 0.78 (0.50,1.21) 0.98 (0.63,1.54) 0.92 0.43 
Pooled 
        Never smokers 678 1 (ref) 1.31 (1.01,1.70) 1.22 (0.92,1.60) 1.42 (1.07,1.88) 1.66 (1.23,2.22) 0.001 
 Ever smokers 911 1 (ref) 1.08 (0.87,1.34) 0.89 (0.71,1.12) 1.19 (0.95,1.49) 1.07 (0.83,1.37) 0.51 0.10 
         Advanced AMD 
        NHS 
        Never smokers 379 1 (ref) 1.07 (0.77,1.49) 1.01 (0.71,1.43) 0.78 (0.53,1.14) 1.04 (0.7,1.55) 0.85 
 Ever smokers 631 1 (ref) 1.05 (0.81,1.37) 1.23 (0.94,1.61) 1.18 (0.89,1.57) 1.09 (0.8,1.49) 0.57 0.39 
HPFS 
        Never smokers 126 1 (ref) 0.91 (0.52,1.59) 0.80 (0.45,1.44) 0.83 (0.45,1.51) 0.94 (0.50,1.76) 0.83 
 Ever smokers 220 1 (ref) 1.20 (0.78,1.85) 1.08 (0.68,1.69) 0.93 (0.58,1.49) 1.06 (0.65,1.73) 0.87 0.95 
Pooled 
        Never smokers 505 1 (ref) 1.03 (0.78,1.37) 0.95 (0.71,1.28) 0.79 (0.57,1.09) 1.02 (0.73,1.42) 0.78 
 Ever smokers 851 1 (ref) 1.10 (0.87,1.37) 1.19 (0.94,1.49) 1.12 (0.88,1.42) 1.09 (0.84,1.41) 0.66 0.57 
Multivariate model included: age (continuous), race (Caucasians or not), BMI (<18.5, 18.5-23, 23-25, 25-30, 30-35, ≥ 35 kg/m2), physical activity 
(<3, 3-8.9, 9-17.9, 18-26.9, ≥27 MET-h/wk), current aspirin use (≥1 tablets/wk or none), history of hypertension, history of hypercholesterolemia, 
total calories, DHA and LA (all in quintiles). In the NHS, models were additionally adjusted for postmenopausal status and menopausal hormone 
use (never, current and past)  
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Supplementary Table 3.2. The associations between intake of ALA and AMD stratified by age 
 
No. of cases Q1 Q2 Q3 Q4 Q5 p trend p interaction 
Intermediate AMD 
       NHS 
        Age<73 years old 710 1 (ref) 1.07 (0.83,1.38) 1.00 (0.77,1.31) 1.28 (0.98,1.67) 1.25 (0.94,1.66) 0.08 0.48 
Age≥73 years old 499 1 (ref) 1.43 (1.06,1.91) 1.11 (0.80,1.54) 1.52 (1.10,2.10) 1.39 (0.97,1.98) 0.11 
 HPFS 
        Age<73 years old 154 1 (ref) 1.45 (0.83,2.51) 1.24 (0.69,2.23) 1.30 (0.72,2.35) 1.83 (1.02,3.3) 0.07 0.2 
Age≥73 years old 226 1 (ref) 0.86 (0.57,1.30) 0.78 (0.51,1.20) 0.90 (0.59,1.38) 0.90 (0.56,1.43) 0.76 
 Pooled 
        Age<73 years old 864 1 (ref) 1.14 (0.91,1.43) 1.05 (0.82,1.33) 1.30 (1.02,1.65) 1.37 (1.06,1.76) 0.009 0.49 
Age≥73 years old 725 1 (ref) 1.21 (0.95,1.53) 0.98 (0.76,1.27) 1.27 (0.98,1.64) 1.20 (0.91,1.59) 0.27 
 
         Advanced AMD 
        NHS 
        Age<73 years old 494 1 (ref) 1.21 (0.90,1.63) 1.25 (0.92,1.70) 1.00 (0.72,1.39) 1.06 (0.75,1.50) 0.82 
 Age≥73 years old 516 1 (ref) 0.95 (0.71,1.26) 1.03 (0.77,1.39) 1.03 (0.75,1.40) 1.08 (0.77,1.52) 0.56 0.76 
HPFS 
        Age<73 years old 133 1 (ref) 2.00 (1.09,3.68) 1.98 (1.06,3.70) 1.63 (0.84,3.16) 1.81 (0.90,3.62) 0.32 
 Age≥73 years old 213 1 (ref) 0.80 (0.53,1.22) 0.68 (0.43,1.06) 0.68 (0.43,1.07) 0.76 (0.48,1.22) 0.27 0.09 
Pooled 
        Age<73 years old 627 1 (ref) 1.35 (1.03,1.76) 1.40 (1.07,1.85) 1.15 (0.86,1.54) 1.27 (0.93,1.72) 0.44 
 Age≥73 years old 729 1 (ref) 0.91 (0.71,1.15) 0.91 (0.71,1.16) 0.90 (0.70,1.17) 0.96 (0.73,1.27) 0.83 0.27 
The median age of AMD onset was 73 years old. 
Multivariate model included: age (continuous), race (Caucasians or not), BMI (<18.5, 18.5-23, 23-25, 25-30, 30-35, ≥ 35 kg/m2), pack-years of 
smoking (never, 1-9, 10-24, 25-44, 45-64, ≥65y), physical activity (<3, 3-8.9, 9-17.9, 18-26.9, ≥27 MET-h/wk), current aspirin use (≥1 tablets/wk 
or none), history of hypertension, history of hypercholesterolemia, total calories, DHA and LA (all in quintiles). In the NHS, models were 
additionally adjusted for postmenopausal status and menopausal hormone use (never, current and past) 
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Supplementary Table 3.3. Stepwise regression models for erythrocyte cis and trans ALA 
cis ALA
¶
 
 
trans ALA-B
¶
 
 
trans ALA C+ D
¶
 
N=395  N=392  N=391 
Mean ± SD, %: 0.13 ± 0.04 
 
Mean ± SD, %: 0.01 ± 0.004 
 
Mean ± SD, %: 0.03 ± 0.01 
Food β p  
 
Food β p  
 
Food β p  
Mayonnaise 0.31 <.0001 
 
Mayonnaise 0.31 <.0001 
 
Beef  -0.27 0.004 
Broccoli 0.20 0.03 
 
Pie (store-made) 1.35 0.01 
 
Butter -0.07 0.007 
    
Peanuts -0.21 0.02 
 
Ice cream -0.22 0.02 
    
Brownie 0.86 0.03 
 
Muffin 0.28 0.03 
    
Oil & vinegar dressing 0.12 0.03 
 
Chicken w/ skin -0.25 0.04 
R
2
=0.07   R
2
=0.10   R
2
=0.08 
¶
Because of missing data or outliers, sample size for each model was not the same 
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Supplementary Table 3.4. Pearson correlations between erythrocyte cis 
and trans ALA 
 
cis ALA trans ALA-B trans ALA-C+ D 
cis ALA  
1   
trans ALA-B  0.65 
(n=392) 
1  
trans ALA-C+ D 0.17 
(n=391) 
0.20 
(n=388) 
1 
P<.001 for all the correlation coefficients.   
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Supplementary Table 3.5. Stepwise regression models for plasma and erythrocyte cis ALA among previously measured blood 
samples 
 
NHS
ǂ
 
 
HPFS
§
 
 
Food 
Cohort
φ
,
 % 
β SE p 
 
  Food 
Cohort
φ
,
 % 
β SE p 
ALA 
            
Plasma
¶
 Mayonnaise 15.4 0.11 0.03 <.0001 
 
Plasma
¶
 Mayonnaise 11.32 0.16 0.04 <.0001 
(Mean ± 
SD, %) 
Iceberg lettuce 12.4 0.05 0.02 0.005 
 
(Mean ± SD, %) 
Beef, pork or 
lamb 
4.63 -0.18 0.07 0.009 
(0.49 ± 0.16) Beef, pork or lamb 5.4 -0.11 0.04 0.002 
 
(0.64 ± 0.26) American cheese 2.79 -0.09 0.03 0.002 
n=1,810 American cheese 3.7 -0.05 0.02 0.009 
 
n=1,389 Dark bread 0.75 0.02 0.01 0.03 
 
Oil & vinegar dressing 2.0 0.06 0.02 0.009 
  
Chicken w/o skin 2.52 0.10 0.05 0.04 
 
R
2
 = 0.03 
      
R
2 
= 0.03 
    
 
                        
Erythrocyte
¶
 Mayonnaise 15.4 0.14 0.03 <.0001 
 
Erythrocyte
¶
 Mayonnaise 11.32 0.12 0.04 0.004 
(Mean ± 
SD, %) 
Beef, pork or lamb 5.4 -0.08 0.04 0.04 
 
(Mean ± SD, %) 
Beef, pork or 
lamb 
4.63 -0.22 0.07 0.002 
(0.15 ± 0.05) Oil & vinegar dressing 2.0 0.09 0.03 0.0004 
 
(0.17 ± 0.04) American cheese 2.79 -0.09 0.03 0.004 
n=2,033 
      
n=1,414 Processed meat 1.82 -0.09 0.04 0.02 
        
Pizza 1.78 -0.27 0.13 0.04 
  R
2
  = 0.02             R
2
 = 0.03         
ǂ
 1986-1990 average percent contribution to total intake in the NHS full cohort 
§
 1990-1994 average percent contribution to total intake in the HPFS full cohort 
φ 
% contribution to the calculated intake in the cohort 
¶ 
Mean level was expressed as the percentage of total fatty acids; biomarker concentrations were adjusted for age, BMI, pack-year of smoking, 
fasting status, case-control status, menopausal status and hormone therapy 
¶
 Total calories were forced into all models 
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Supplemental Figures 
 
Supplementary Figure 1.1. Predicted plasma carotenoid scores and HRs of total AMD according to current menopausal 
hormone use status among postmenopausal women 
 
 
 
There were 1,221 cases in non-current users group and 413 cases in current users group 
All the HRs were comparing the fifth to the bottom quintile 
Multivariate models were adjusted for: age (continuous), BMI (≥30 kg/m2), pack-years of smoking (never, 1-9, 10-24, 25-44, 45-64,   
≥65y), physical activity (<3, 3-8.9, 9-17.9, 18-26.9, ≥27 MET-h/wk), current aspirin use (≥1 tablets/wk or none), aHEI (excluding fruits and 
vegetables)  
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Supplementary Figure 1.2. Predicted plasma carotenoid scores and pooled HRs of advanced AMD according to age and 
smoking status 
 
 
A) Multivariate models were adjusted for the same variables as in Supplementary Figure 1.1 and additionally adjusted for race in HPFS; 651 cases 
in age<75 group (477 from NHS and 174 cases from HPFS); 467 cases in age≥75 group (296 from NHS and 171 cases from HPFS). 
B) Multivariate models were adjusted for the same variables as in A) except pack-year of smoking; 425 cases in never smokers group (289 from 
NHS and 136 cases from HPFS); 693 cases in ever smokers group (484 from NHS and 209 cases from HPFS) 
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Supplementary Figure 1.3. Hazard ratios comparing extreme quintiles for the associations between predicted plasma 
carotenoid scores and AMD in the NHS 
  
 
*: p for trend <0.05 
Multivariate models were adjusted for the same variables as in the Supplementary Figure 1.1  
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Supplementary Figure 3.1. The associations between different types of fatty acids and intermediate AMD 
 
 
All the HRs were adjusted for the same variables as in the Figure 3.2
 122 
 
Supplementary Figure 3.2. The associations between different types of fatty acids and advanced AMD 
 
 
All the HRs were adjusted for the same variables as in the Figure 3.2 
